|
FR2470599A1
(fr)
*
|
1979-12-07 |
1981-06-12 |
Panoz Donald |
Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
|
|
US4344929A
(en)
*
|
1980-04-25 |
1982-08-17 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
JPS5770816A
(en)
*
|
1980-10-17 |
1982-05-01 |
Ono Pharmaceut Co Ltd |
Multilayered film preparation of prostagladin of prolonged action
|
|
FR2525474A1
(fr)
*
|
1982-04-26 |
1983-10-28 |
Roussel Uclaf |
Nouvelle forme pharmaceutique orale de clometacine
|
|
US4478596A
(en)
*
|
1982-11-26 |
1984-10-23 |
Michelson Paul E |
Delivery system for physiologically active agents
|
|
US4613330A
(en)
*
|
1982-11-26 |
1986-09-23 |
Michelson Paul E |
Delivery system for desired agents
|
|
NZ206600A
(en)
*
|
1983-05-11 |
1987-01-23 |
Alza Corp |
Osmotic drug delivery device
|
|
JPH075457B2
(ja)
*
|
1983-08-16 |
1995-01-25 |
ザ ウエルカム フアウンデ−シヨン リミテツド |
調節された方法による有効成分の放出を可能にする医薬組成物
|
|
US4670578A
(en)
*
|
1983-08-29 |
1987-06-02 |
Merck & Co., Inc. |
Process for crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters
|
|
EP0137364A3
(en)
*
|
1983-09-23 |
1986-10-22 |
Merck & Co. Inc. |
Suppository form of an osmotic therapeutic system
|
|
US4627850A
(en)
*
|
1983-11-02 |
1986-12-09 |
Alza Corporation |
Osmotic capsule
|
|
GB2150434B
(en)
*
|
1983-12-01 |
1987-11-04 |
Alza Corp |
Constant rate release systems
|
|
GB2150830B
(en)
*
|
1983-12-05 |
1987-08-19 |
Alza Corp |
Drug dispenser
|
|
US4725427A
(en)
*
|
1984-03-13 |
1988-02-16 |
Albion International, Inc. |
Effervescent vitamin-mineral granule preparation
|
|
US4717566A
(en)
*
|
1984-03-19 |
1988-01-05 |
Alza Corporation |
Dosage system and method of using same
|
|
US4595583A
(en)
*
|
1984-03-19 |
1986-06-17 |
Alza Corporation |
Delivery system controlled administration of beneficial agent to ruminants
|
|
DE3586445T2
(de)
|
1984-06-26 |
1993-01-14 |
Merck & Co Inc |
Kondensierte benzo-laktam-verbindungen und deren pharmazeutische zusammensetzungen.
|
|
US4693895A
(en)
*
|
1984-10-26 |
1987-09-15 |
Alza Corporation |
Colon delivery system
|
|
US4624847A
(en)
*
|
1985-04-22 |
1986-11-25 |
Alza Corporation |
Drug delivery device for programmed delivery of beneficial drug
|
|
US4627971A
(en)
*
|
1985-04-22 |
1986-12-09 |
Alza Corporation |
Osmotic device with self-sealing passageway
|
|
US4675174A
(en)
*
|
1985-08-16 |
1987-06-23 |
Alza Corporation |
Veterinary dispenser delivering beneficial agent by gas power generated in situ
|
|
US4723957A
(en)
*
|
1986-02-07 |
1988-02-09 |
Alza Corp. |
System for delivering drug with enhanced bioacceptability
|
|
US4971790A
(en)
*
|
1986-02-07 |
1990-11-20 |
Alza Corporation |
Dosage form for lessening irritation of mocusa
|
|
US4662880A
(en)
*
|
1986-03-14 |
1987-05-05 |
Alza Corporation |
Pseudoephedrine, brompheniramine therapy
|
|
US4753802A
(en)
*
|
1986-03-19 |
1988-06-28 |
Alza Corporation |
Verapamil dosage form
|
|
US4847093A
(en)
*
|
1986-06-19 |
1989-07-11 |
Alza Corporation |
Dosage form with means for governing rate of gas formation
|
|
US5099063A
(en)
*
|
1986-11-05 |
1992-03-24 |
Merck & Co., Inc. |
Certain phosphinic acid derivatives having antibacterial activity
|
|
US4715994A
(en)
*
|
1986-11-05 |
1987-12-29 |
Merck & Co., Inc. |
Novel antibacterial agents and potentiators of carbapenem antibiotics
|
|
US5143908A
(en)
*
|
1986-11-05 |
1992-09-01 |
Merck & Co., Inc. |
Antibacterial agents and potentiators of carbapenem antibiotics
|
|
US4957494A
(en)
*
|
1987-06-25 |
1990-09-18 |
Alza Corporation |
Multi-layer delivery system
|
|
US5938654A
(en)
*
|
1987-06-25 |
1999-08-17 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
|
US5110597A
(en)
*
|
1987-06-25 |
1992-05-05 |
Alza Corporation |
Multi-unit delivery system
|
|
US5023088A
(en)
*
|
1987-06-25 |
1991-06-11 |
Alza Corporation |
Multi-unit delivery system
|
|
US5499979A
(en)
*
|
1987-06-25 |
1996-03-19 |
Alza Corporation |
Delivery system comprising kinetic forces
|
|
US4874388A
(en)
*
|
1987-06-25 |
1989-10-17 |
Alza Corporation |
Multi-layer delivery system
|
|
US5041644A
(en)
*
|
1987-07-06 |
1991-08-20 |
Merck & Co., Inc. |
Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid
|
|
JPS6413097A
(en)
*
|
1987-07-06 |
1989-01-17 |
Mitsubishi Chem Ind |
Phosphonic acid derivative
|
|
EP0318066B1
(en)
|
1987-09-22 |
1992-07-29 |
Merck & Co. Inc. |
Aryl-substituted thiophene 3-ols, derivatives and analogs, as lipoxygenase inhibitors
|
|
US5030732A
(en)
*
|
1988-03-03 |
1991-07-09 |
Merck & Co., Inc. |
Aminoethylphosphinic acid derivatives
|
|
CH675537A5
(es)
*
|
1988-03-25 |
1990-10-15 |
Ciba Geigy Ag |
|
|
US5211957A
(en)
*
|
1988-03-25 |
1993-05-18 |
Ciba-Geigy Corporation |
Solid rapidly disintegrating dosage form
|
|
US5145990A
(en)
*
|
1988-10-28 |
1992-09-08 |
Merck & Co., Inc. |
Phosphorous containing dhp enzyme inhibitors
|
|
US5147867A
(en)
*
|
1988-10-28 |
1992-09-15 |
Merck & Co., Inc. |
Phosphorus containing enzyme inhibitors
|
|
US4962097A
(en)
*
|
1988-10-28 |
1990-10-09 |
Merck & Co., Inc. |
Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors
|
|
US4942039A
(en)
*
|
1989-05-09 |
1990-07-17 |
Miles Inc. |
Effervescent analgesic antacid composition having reduced sodium content
|
|
US5223264A
(en)
*
|
1989-10-02 |
1993-06-29 |
Cima Labs, Inc. |
Pediatric effervescent dosage form
|
|
US5089530A
(en)
|
1990-08-03 |
1992-02-18 |
Merck & Co., Inc. |
Novel fermentation product with antiparasitic activity
|
|
US5443459A
(en)
*
|
1991-01-30 |
1995-08-22 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
|
SG84487A1
(en)
|
1991-04-17 |
2001-11-20 |
Merck & Co Inc |
Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
|
|
US5198229A
(en)
*
|
1991-06-05 |
1993-03-30 |
Alza Corporation |
Self-retaining gastrointestinal delivery device
|
|
US5223265A
(en)
*
|
1992-01-10 |
1993-06-29 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery
|
|
US5639782A
(en)
*
|
1992-03-04 |
1997-06-17 |
Center For Innovative Technology |
Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
|
|
US5463083A
(en)
*
|
1992-07-13 |
1995-10-31 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
US5434151A
(en)
*
|
1992-08-24 |
1995-07-18 |
Cytomed, Inc. |
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
|
DE69329550T2
(de)
|
1992-07-13 |
2001-05-31 |
Cytomed, Inc. |
2,5-diaryl tetrahydro-thiopene, -furane und analoge zur behandlung von entzündungs-und immunkrankheiten
|
|
US5498255A
(en)
*
|
1993-08-17 |
1996-03-12 |
Alza Corporation |
Osmotic device for protracted pulsatile delivery of agent
|
|
US5403952A
(en)
*
|
1993-10-08 |
1995-04-04 |
Merck & Co., Inc. |
Substituted cyclic derivatives as novel antidegenerative agents
|
|
US5792776A
(en)
*
|
1994-06-27 |
1998-08-11 |
Cytomed, Inc., |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
US5750565A
(en)
*
|
1995-05-25 |
1998-05-12 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
US5703093A
(en)
*
|
1995-05-31 |
1997-12-30 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
US6348571B1
(en)
|
1994-09-12 |
2002-02-19 |
Northwestern University |
Corticotropin release inhibiting factor and methods of using same
|
|
US5767113A
(en)
*
|
1995-05-10 |
1998-06-16 |
The Salk Institute For Biological Studies |
Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
|
|
CA2220451A1
(en)
*
|
1995-05-17 |
1996-11-21 |
Cedars-Sinai Medical Center |
Methods and compositions for improving digestion and absorption in the small intestine
|
|
US7048906B2
(en)
|
1995-05-17 |
2006-05-23 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
|
|
US6861053B1
(en)
*
|
1999-08-11 |
2005-03-01 |
Cedars-Sinai Medical Center |
Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
|
|
US6558708B1
(en)
|
1995-05-17 |
2003-05-06 |
Cedars-Sinai Medical Center |
Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
|
|
US5817335A
(en)
*
|
1995-05-26 |
1998-10-06 |
Alza Corporation |
Osmotic device with high drug loading and delayed activation of drug delivery
|
|
US5756540A
(en)
*
|
1995-06-02 |
1998-05-26 |
Mcw Research Foundation, Inc. |
Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
|
|
US5800422A
(en)
*
|
1995-06-02 |
1998-09-01 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery and complete drug release
|
|
US5741815A
(en)
*
|
1995-06-02 |
1998-04-21 |
Lai; Ching-San |
Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
|
|
US6372713B1
(en)
*
|
1995-09-08 |
2002-04-16 |
The Board Of Trustees Of Northwestern University |
Anti-depressant effects of corticotropin release inhibiting factor
|
|
US5747532A
(en)
*
|
1995-11-21 |
1998-05-05 |
Medinox, Inc. |
Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
|
|
US6723531B2
(en)
*
|
1996-04-05 |
2004-04-20 |
The Salk Institute For Biological Studies |
Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
|
US5902605A
(en)
*
|
1996-04-18 |
1999-05-11 |
Alza Corporation |
Drug delivery device with minimal residual drug retention
|
|
US5785688A
(en)
*
|
1996-05-07 |
1998-07-28 |
Ceramatec, Inc. |
Fluid delivery apparatus and method
|
|
US5939460A
(en)
*
|
1996-07-08 |
1999-08-17 |
Idun Pharmaceuticals, Inc. |
Method of inhibiting NADPH oxidase
|
|
US5677318A
(en)
*
|
1996-07-11 |
1997-10-14 |
Merck Frosst Canada, Inc. |
Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
|
|
US5922761A
(en)
*
|
1996-09-06 |
1999-07-13 |
Medinox, Inc. |
Methods for in vivo reduction of iron levels and compositions useful therefor
|
|
AU746790B2
(en)
|
1996-09-10 |
2002-05-02 |
Medinox, Inc. |
Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
|
|
US5858402A
(en)
*
|
1997-02-11 |
1999-01-12 |
Medinox, Inc. |
Methods for in vivo reduction of cyanide levels and compositions useful therefor
|
|
US5916910A
(en)
|
1997-06-04 |
1999-06-29 |
Medinox, Inc. |
Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
|
|
US5985592A
(en)
*
|
1997-06-05 |
1999-11-16 |
Dalhousie University |
Uses for pentoxifylline or functional derivatives/metabolites thereof
|
|
US6294350B1
(en)
|
1997-06-05 |
2001-09-25 |
Dalhousie University |
Methods for treating fibroproliferative diseases
|
|
US5840721A
(en)
*
|
1997-07-09 |
1998-11-24 |
Ontogen Corporation |
Imidazole derivatives as MDR modulators
|
|
US7105496B2
(en)
*
|
1998-07-23 |
2006-09-12 |
Northwestern University |
Methods and compositions for inhibiting angiogenesis
|
|
US6797691B1
(en)
*
|
1997-07-23 |
2004-09-28 |
Northwestern University |
Methods and compositions for inhibiting angiogenesis
|
|
US20030220234A1
(en)
*
|
1998-11-02 |
2003-11-27 |
Selvaraj Naicker |
Deuterated cyclosporine analogs and their use as immunodulating agents
|
|
CA2305703A1
(en)
|
1997-10-10 |
1999-04-22 |
David W. Christianson |
Compositions and methods for inhibiting arginase activity
|
|
JP2001519386A
(ja)
|
1997-10-15 |
2001-10-23 |
トーマス・ジェファーソン・ユニバーシティ |
哺乳動物における血管収縮または血管痙攣を予防または緩和するための一酸化窒素供与体組成物、方法、装置およびキット
|
|
US6750201B1
(en)
*
|
1997-10-17 |
2004-06-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
|
|
US6756491B2
(en)
|
1998-01-09 |
2004-06-29 |
The Salk Institute For Biological Studies |
Steroid-activated nuclear receptors and uses therefor
|
|
US6984773B1
(en)
|
1998-01-09 |
2006-01-10 |
The Salk Institute For Biological Studies |
Transgenic mice expressing a human SXR receptor polypeptide
|
|
US6107274A
(en)
*
|
1998-03-16 |
2000-08-22 |
Ontogen Corporation |
Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
|
|
US6287605B1
(en)
*
|
1998-04-17 |
2001-09-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treatment and prevention of HIV-1 infection
|
|
WO1999058640A2
(en)
|
1998-05-11 |
1999-11-18 |
Philadelphia Health And Education Corporation |
Mct-1, a human oncogene
|
|
US6333318B1
(en)
*
|
1998-05-14 |
2001-12-25 |
The Salk Institute For Biological Studies |
Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
|
US20030220258A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Robbert Benner |
Treatment of ischemic events
|
|
US20050203187A1
(en)
*
|
1998-06-01 |
2005-09-15 |
Verbiscar Anthony J. |
Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
|
|
US6093743A
(en)
*
|
1998-06-23 |
2000-07-25 |
Medinox Inc. |
Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
|
|
US6596770B2
(en)
|
2000-05-05 |
2003-07-22 |
Medinox, Inc. |
Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
|
|
US6265420B1
(en)
|
1998-06-23 |
2001-07-24 |
Medinox, Inc. |
Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
|
|
US20030064917A1
(en)
*
|
1998-07-23 |
2003-04-03 |
Crawford Susan E. |
Methods and compositions for inhibiting angiogenesis
|
|
WO2000009118A1
(en)
|
1998-08-13 |
2000-02-24 |
The Wistar Institute |
Methods for reducing atherosclerotic plaques
|
|
US6565854B2
(en)
|
1998-08-13 |
2003-05-20 |
Philadelphia Health And Education Corporation |
Antimicrobial histone H1 compositions, kits, and methods of use thereof
|
|
US6646113B1
(en)
|
1998-09-17 |
2003-11-11 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
|
|
US20020138856A1
(en)
*
|
1998-10-23 |
2002-09-26 |
Northwestern University |
Compositions and methods useful for treatment of depressive disorder based on an animal model
|
|
ATE376824T1
(de)
|
1999-01-13 |
2007-11-15 |
Alchemia Oncology Pty Ltd |
Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
|
|
US7282489B2
(en)
*
|
2000-01-19 |
2007-10-16 |
The Children's Hospital Of Philadelphia |
Compositions and methods for performing reverse gene therapy
|
|
AU2732000A
(en)
|
1999-01-19 |
2000-08-01 |
Children's Hospital Of Philadelphia, The |
Reverse gene therapy
|
|
US6395029B1
(en)
|
1999-01-19 |
2002-05-28 |
The Children's Hospital Of Philadelphia |
Sustained delivery of polyionic bioactive agents
|
|
US7141417B1
(en)
|
1999-02-25 |
2006-11-28 |
Thomas Jefferson University |
Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
|
|
CA2364653A1
(en)
|
1999-02-25 |
2000-08-31 |
Merck Frosst Canada & Co. |
Pde iv inhibiting compounds, compositions and methods of treatment
|
|
US6221855B1
(en)
|
1999-03-11 |
2001-04-24 |
Wake Forest University |
Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
US6025502A
(en)
*
|
1999-03-19 |
2000-02-15 |
The Trustees Of The University Of Pennsylvania |
Enantopselective synthesis of methyl phenidate
|
|
US6251927B1
(en)
|
1999-04-20 |
2001-06-26 |
Medinox, Inc. |
Methods for treatment of sickle cell anemia
|
|
ATE525390T1
(de)
|
1999-04-27 |
2011-10-15 |
Univ Pennsylvania |
Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
|
|
US6420545B1
(en)
*
|
1999-05-24 |
2002-07-16 |
The Trustees Of The University Of Pennsylvania |
CD4-independent HIV envelope proteins as vaccines and therapeutics
|
|
US7033780B1
(en)
*
|
1999-06-14 |
2006-04-25 |
Millennium Pharmaceuticals, Inc. |
Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
|
|
US7160694B2
(en)
|
1999-06-14 |
2007-01-09 |
Millennium Pharmaceuticals, Inc. |
Nucleic acids encoding TANGO405 and functional fragments and uses thereof
|
|
US6964854B1
(en)
*
|
1999-07-13 |
2005-11-15 |
Science & Technology Corporation |
Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
|
|
AU782401B2
(en)
|
1999-10-08 |
2005-07-28 |
Taiji Biomedical, Inc. |
Methods of enhancing chemotherapy
|
|
US20020147197A1
(en)
*
|
1999-10-08 |
2002-10-10 |
Newman Michael J. |
Methods and compositions for enhancing pharmaceutical treatments
|
|
US6274627B1
(en)
|
1999-10-12 |
2001-08-14 |
Medinox, Inc. |
Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
|
|
ES2339326T3
(es)
|
1999-10-12 |
2010-05-19 |
Chemocentryx, Inc. |
Receptor de quimioquina.
|
|
US7057015B1
(en)
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
|
JP3417370B2
(ja)
|
1999-12-09 |
2003-06-16 |
株式会社村田製作所 |
非可逆回路素子及び通信機装置
|
|
US6559128B1
(en)
|
2000-01-21 |
2003-05-06 |
Northwestern University |
Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
|
|
US20030212021A1
(en)
*
|
2001-01-25 |
2003-11-13 |
Frost Gregory I. |
Myeloid colony stimulating factor and uses thereof
|
|
US6464688B1
(en)
|
2000-02-15 |
2002-10-15 |
Microsolutions, Inc. |
Osmotic pump delivery system with flexible drug compartment
|
|
JP2001320205A
(ja)
|
2000-03-02 |
2001-11-16 |
Murata Mfg Co Ltd |
非可逆回路素子および通信装置
|
|
US7358330B2
(en)
*
|
2001-03-29 |
2008-04-15 |
Biotempt B.V. |
Immunoregulatory compositions
|
|
ES2272462T3
(es)
*
|
2000-04-07 |
2007-05-01 |
The Trustees Of The University Of Pennsylvania |
Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
|
|
US6509315B1
(en)
|
2000-04-07 |
2003-01-21 |
The Trustees Of The University Of Pennsylvania |
Didemnin analogs and fragments and methods of making and using them
|
|
ATE254118T1
(de)
|
2000-05-15 |
2003-11-15 |
Darwin Discovery Ltd |
Hydroxamsäure derivate
|
|
US6613801B2
(en)
*
|
2000-05-30 |
2003-09-02 |
Transtech Pharma, Inc. |
Method for the synthesis of compounds of formula I and their uses thereof
|
|
US6908741B1
(en)
*
|
2000-05-30 |
2005-06-21 |
Transtech Pharma, Inc. |
Methods to identify compounds that modulate RAGE
|
|
WO2001091730A1
(en)
|
2000-05-31 |
2001-12-06 |
Drugtech Corporation |
Mineral supplement
|
|
WO2001097752A2
(en)
*
|
2000-06-20 |
2001-12-27 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising urokinase for modulating muscle contractility and angiogenisis
|
|
US6429223B1
(en)
|
2000-06-23 |
2002-08-06 |
Medinox, Inc. |
Modified forms of pharmacologically active agents and uses therefor
|
|
AUPQ879500A0
(en)
*
|
2000-07-14 |
2000-08-10 |
Meditech Research Limited |
Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
|
|
US9066919B2
(en)
*
|
2000-07-14 |
2015-06-30 |
Alchemia Oncology Pty Limited |
Hyaluronan as a chemo-sensitizer in the treatment of cancer
|
|
JP2004504063A
(ja)
|
2000-07-19 |
2004-02-12 |
アドバンスド リサーチ ＆ テクノロジー インスティテュート |
新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法
|
|
AU2001290629A1
(en)
*
|
2000-09-07 |
2002-03-22 |
Boehringer Ingelheim International G.M.B.H |
Heat shock response and virus replication
|
|
AU2001296915A1
(en)
*
|
2000-09-26 |
2002-04-08 |
Sidney Kimmel Cancer Center |
Inhibition of antigen presentation with poorly catabolized polymers
|
|
US20040102367A1
(en)
*
|
2001-02-23 |
2004-05-27 |
Gage Fred H |
Gene expression system based on chimeric receptors
|
|
CA2440037C
(en)
*
|
2001-03-05 |
2010-02-16 |
Transtech Pharma, Inc. |
Benzimidazole derivatives for modulating the rage receptor
|
|
JP2005500254A
(ja)
*
|
2001-03-05 |
2005-01-06 |
トランス テック ファーマ，インコーポレイテッド |
治療因子としてのカルボキサミド誘導体
|
|
WO2002070667A2
(en)
*
|
2001-03-05 |
2002-09-12 |
Transtech Pharma, Inc. |
High level insect expression of rage proteins
|
|
US7294472B2
(en)
*
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
|
US7208279B2
(en)
*
|
2001-03-14 |
2007-04-24 |
Caden Biosciences, Inc. |
Method for identifying inhibitors of G protein coupled receptor signaling
|
|
ITMI20010733A1
(it)
|
2001-04-05 |
2002-10-05 |
Recordati Chem Pharm |
Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
|
|
US6727287B2
(en)
|
2001-04-16 |
2004-04-27 |
Pts International, Inc. |
Toluene sulfonamide-containing anti-tumor composition and method of use thereof
|
|
US6632217B2
(en)
*
|
2001-04-19 |
2003-10-14 |
Microsolutions, Inc. |
Implantable osmotic pump
|
|
CN1157388C
(zh)
*
|
2001-05-29 |
2004-07-14 |
北京大学 |
哌嗪基二硫代甲酸酯类化合物,它们的制备方法和在抗肿瘤药物中的应用
|
|
RU2259825C9
(ru)
|
2001-06-18 |
2006-04-10 |
БиоДием Лимитед |
Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
|
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
|
US6884619B2
(en)
|
2001-07-17 |
2005-04-26 |
Yale University |
Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
|
|
WO2003007793A2
(en)
*
|
2001-07-17 |
2003-01-30 |
Yale University |
Compositions, methods, and kits related to treating and diagnosing hypertension
|
|
GB0119396D0
(en)
*
|
2001-08-09 |
2001-10-03 |
Celltech R&D Ltd |
Hydroxamic acid derivatives
|
|
US9056048B2
(en)
*
|
2001-08-16 |
2015-06-16 |
The Trustees Of The University Of Pennsylvania |
Synthesis and use of cationic steroids for anti-inflammatory drug therapy
|
|
DE60236520D1
(de)
*
|
2001-08-16 |
2010-07-08 |
Univ Pennsylvania |
Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
|
|
WO2003018062A1
(en)
*
|
2001-08-27 |
2003-03-06 |
Meditech Research Limited |
Improved therapeutic protocols
|
|
US20030069071A1
(en)
*
|
2001-09-28 |
2003-04-10 |
Tim Britt |
Entertainment monitoring system and method
|
|
PL210795B1
(pl)
*
|
2001-10-19 |
2012-03-30 |
Isotechnika Inc |
Sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (E), sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (Z), sposób stereoselektywnej syntezy izomeru (E) ISATX247, sposób stereoselektywnej syntezy izomeru (Z) ISATX247 i sposób wytwarzania mieszaniny izomerów ISATX247
|
|
US6555563B1
(en)
|
2001-11-16 |
2003-04-29 |
Medinox, Inc. |
Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
|
|
US7413866B2
(en)
*
|
2001-11-30 |
2008-08-19 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
US7253007B2
(en)
*
|
2001-11-30 |
2007-08-07 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
US7442512B2
(en)
*
|
2001-11-30 |
2008-10-28 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
US7871619B2
(en)
*
|
2001-11-30 |
2011-01-18 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
|
PE20030701A1
(es)
*
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
|
PL370989A1
(en)
|
2001-12-21 |
2005-06-13 |
Novo Nordisk A/S |
Amide derivatives as gk activators
|
|
AR038136A1
(es)
|
2002-01-24 |
2004-12-29 |
Merck Frosst Canada Inc |
Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
|
|
US20030175346A1
(en)
*
|
2002-02-01 |
2003-09-18 |
Anne Billotte |
Osmotic delivery system
|
|
US20030161882A1
(en)
*
|
2002-02-01 |
2003-08-28 |
Waterman Kenneth C. |
Osmotic delivery system
|
|
TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US7378111B2
(en)
*
|
2002-02-20 |
2008-05-27 |
The Trustees Of The University Of Pennsylvania |
Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
|
|
DK1482931T3
(da)
*
|
2002-03-05 |
2011-12-19 |
Transtech Pharma Inc |
Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
|
|
CA2481320A1
(en)
|
2002-04-11 |
2003-10-23 |
Merck & Co., Inc. |
1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
|
|
US7622117B2
(en)
*
|
2002-04-17 |
2009-11-24 |
Dynamis Therapeutics, Inc. |
3-deoxyglucosone and skin
|
|
EP1503754B1
(en)
*
|
2002-04-19 |
2005-11-23 |
Yissum Research Development Company, of The Hebrew University of Jerusalem |
Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
|
|
EP1501511A4
(en)
*
|
2002-05-06 |
2006-06-07 |
Univ Washington |
METHODS OF TREATING GLAUCOMA AND OTHER CONDITIONS INDUCED BY EXPRESSION OF NOS-2 BY INHIBITING THE EGFR PATHWAY
|
|
AUPS234402A0
(en)
*
|
2002-05-15 |
2002-06-13 |
Auckland Uniservices Limited |
Anti-tumour polycyclic carboxamides
|
|
US20080051428A1
(en)
*
|
2002-05-15 |
2008-02-28 |
Davis Paul J |
Pyrroloquinoline quinone drugs and methods of use thereof
|
|
EP1507756B1
(en)
|
2002-05-24 |
2015-07-22 |
Millennium Pharmaceuticals, Inc. |
Ccr9 inhibitors and methods of use thereof
|
|
US6727241B2
(en)
|
2002-06-12 |
2004-04-27 |
Chemocentryx |
Anti-inflammatory compositions and methods of use
|
|
US7842693B2
(en)
*
|
2002-06-12 |
2010-11-30 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
EP1531822B1
(en)
|
2002-06-12 |
2009-08-05 |
ChemoCentryx Inc |
1-aryl-4-substituted piperazine derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders
|
|
US20050256130A1
(en)
*
|
2002-06-12 |
2005-11-17 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US7589199B2
(en)
*
|
2002-06-12 |
2009-09-15 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US20040077691A1
(en)
*
|
2002-06-21 |
2004-04-22 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
|
US6620813B1
(en)
|
2002-06-21 |
2003-09-16 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
|
PL215132B1
(pl)
|
2002-06-27 |
2013-10-31 |
Novo Nordisk As |
Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
|
|
EP2210892A3
(en)
|
2002-10-04 |
2010-10-27 |
Prana Biotechnology Limited |
Neurologically-active compounds
|
|
WO2004037206A2
(en)
*
|
2002-10-23 |
2004-05-06 |
University Of Hawaii |
Methods for diagnosing and treating pre-term labor
|
|
AU2003278565A1
(en)
*
|
2002-10-25 |
2004-05-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
|
|
US7247725B2
(en)
|
2002-10-30 |
2007-07-24 |
Merck & Co., Inc. |
Gamma-aminoamide modulators of chemokine receptor activity
|
|
ATE468114T1
(de)
|
2002-11-08 |
2010-06-15 |
High Point Pharmaceuticals Llc |
Sichere chemische entkuppler zur behandlung von fettsucht
|
|
US20050143449A1
(en)
*
|
2002-11-15 |
2005-06-30 |
The Salk Institute For Biological Studies |
Non-steroidal farnesoid X receptor modulators and methods for the use thereof
|
|
US20070021466A1
(en)
*
|
2002-11-18 |
2007-01-25 |
Solomon Ungashe |
CCR2 inhibitors and methods of use thereof
|
|
US7420055B2
(en)
|
2002-11-18 |
2008-09-02 |
Chemocentryx, Inc. |
Aryl sulfonamides
|
|
US7227035B2
(en)
*
|
2002-11-18 |
2007-06-05 |
Chemocentryx |
Bis-aryl sulfonamides
|
|
US7741519B2
(en)
|
2007-04-23 |
2010-06-22 |
Chemocentryx, Inc. |
Bis-aryl sulfonamides
|
|
EP2256116A3
(en)
*
|
2002-11-18 |
2011-11-16 |
ChemoCentryx, Inc. |
Aryl sulfonamides
|
|
WO2004047755A2
(en)
*
|
2002-11-22 |
2004-06-10 |
Japan Tobacco Inc. |
Fused bicyclic nitrogen-containing heterocycles
|
|
WO2004050084A2
(en)
*
|
2002-11-29 |
2004-06-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Ace-inhibitors having antioxidant and nitricoxid-donor activity
|
|
ATE427933T1
(de)
*
|
2002-12-20 |
2009-04-15 |
Chemocentryx Inc |
Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
|
|
PT1572672E
(pt)
|
2002-12-20 |
2008-10-02 |
Sosei R & D Ltd |
Benzoxazocinas e sua utilização como inibidores de reabsorção de monoamina
|
|
AU2004204751A1
(en)
*
|
2003-01-09 |
2004-07-29 |
The Trustees Of The University Of Pennsylvania |
Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
|
|
AU2003900927A0
(en)
*
|
2003-02-28 |
2003-03-13 |
Biodiem Ltd |
Growth promotion method
|
|
WO2004084812A2
(en)
*
|
2003-03-21 |
2004-10-07 |
Joullie Madeleine M |
Tamandarin analogs and fragments thereof and methods of making and using
|
|
EP1615698B1
(en)
|
2003-04-11 |
2010-09-29 |
High Point Pharmaceuticals, LLC |
New amide derivatives and pharmaceutical use thereof
|
|
JO2355B1
(en)
|
2003-04-15 |
2006-12-12 |
ميرك شارب اند دوم كوربوريشن |
Hereditary calcitonin polypeptide receptor antagonists
|
|
US8158149B2
(en)
*
|
2004-05-12 |
2012-04-17 |
Chelsea Therapeutics, Inc. |
Threo-DOPS controlled release formulation
|
|
US20060105036A1
(en)
|
2003-05-12 |
2006-05-18 |
Stephen Peroutka |
Threo-dops controlled release formulation
|
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
|
JP2007503469A
(ja)
*
|
2003-05-20 |
2007-02-22 |
トランス テック ファーマ，インコーポレイテッド |
アミロイド症およびそれに関連した疾患を改善するための作用物質としてのｒａｇｅアンタゴニスト
|
|
CN1849318B
(zh)
*
|
2003-07-30 |
2011-10-12 |
里格尔药品股份有限公司 |
用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
|
|
EP1653969A4
(en)
*
|
2003-08-07 |
2006-12-20 |
Japan Tobacco Inc |
PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
|
|
EP2087905A2
(en)
|
2003-08-08 |
2009-08-12 |
Novo Nordisk A/S |
Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
|
|
WO2005025513A2
(en)
*
|
2003-09-12 |
2005-03-24 |
The Regents Of The Univeristy Of California |
Guanidinium derivatives for improved cellular transport
|
|
WO2005033297A1
(en)
*
|
2003-09-19 |
2005-04-14 |
The Rockefeller University |
Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
|
|
RU2381233C2
(ru)
|
2003-09-30 |
2010-02-10 |
Ново Нордиск А/С |
Агонисты рецептора меланокортина
|
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
|
US20100247540A1
(en)
*
|
2003-10-30 |
2010-09-30 |
Chemocentryx, Inc. |
Methods and Compositions For Modulating Angiogenesis
|
|
CA2548105A1
(en)
*
|
2003-12-12 |
2005-06-30 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
|
OA13336A
(en)
*
|
2003-12-15 |
2006-04-13 |
Theramex |
1-N-phenyl-amino-1H-imidazole derivatives and pharmaceutical compositions containing them.
|
|
KR101126225B1
(ko)
|
2004-01-06 |
2012-04-12 |
노보 노르디스크 에이/에스 |
헤테로아릴-유리아 및 글루코키나아제 활성제로서의 그들의 사용
|
|
EP1720545B1
(en)
*
|
2004-03-03 |
2014-10-29 |
ChemoCentryx, Inc. |
Bicyclic and bridged nitrogen heterocycles
|
|
US7435831B2
(en)
*
|
2004-03-03 |
2008-10-14 |
Chemocentryx, Inc. |
Bicyclic and bridged nitrogen heterocycles
|
|
US20060003020A1
(en)
*
|
2004-03-11 |
2006-01-05 |
The Regents Of The University Of Michigan |
Anti-metastatic ability of mibefradil and gadolinium
|
|
WO2005089505A2
(en)
|
2004-03-19 |
2005-09-29 |
Yale University |
Detection, isolation and uses of renalase (monoamine oxidase c)
|
|
JP2007530566A
(ja)
*
|
2004-03-22 |
2007-11-01 |
ミオゲン インコーポレイティッド |
（ｒ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
|
|
EP1737448A1
(en)
*
|
2004-03-22 |
2007-01-03 |
Myogen, Inc. |
(s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
US7169807B2
(en)
*
|
2004-04-09 |
2007-01-30 |
Allergan, Inc. |
10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
|
|
KR101258298B1
(ko)
*
|
2004-06-01 |
2013-04-25 |
유니버시티 오브 버지니아 페이턴트 파운데이션 |
암 및 혈관형성의 이중 소분자 억제제
|
|
AU2005251463A1
(en)
|
2004-06-14 |
2005-12-22 |
Zoser B. Salama |
Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
|
|
US7740861B2
(en)
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
|
US20060292213A1
(en)
*
|
2004-06-23 |
2006-12-28 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of PDE-III mediated diseases
|
|
US8507411B2
(en)
*
|
2004-06-24 |
2013-08-13 |
Wisconsin Alumni Research Foundation |
Neoglycorandomization and digitoxin analogs
|
|
CA2571409C
(en)
*
|
2004-06-24 |
2012-01-24 |
Wisconsin Alumni Research Foundation |
Neoglycorandomization and digitoxin analogs
|
|
ES2327251T3
(es)
*
|
2004-07-02 |
2009-10-27 |
Allergan, Inc. |
Analogos de prostaglandina.
|
|
EP1776459A1
(en)
*
|
2004-08-03 |
2007-04-25 |
Transtech Pharma, Inc. |
Rage fusion proteins and methods of use
|
|
US7906552B2
(en)
*
|
2004-08-10 |
2011-03-15 |
Allergan, Inc. |
Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
|
US7101904B2
(en)
*
|
2004-08-10 |
2006-09-05 |
Allergan, Inc. |
Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
|
US7183310B2
(en)
*
|
2004-08-10 |
2007-02-27 |
Allergan, Inc. |
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
|
EP2494992A1
(en)
|
2004-08-24 |
2012-09-05 |
Merck Sharp & Dohme Corp. |
Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
|
|
WO2006032039A2
(en)
*
|
2004-09-17 |
2006-03-23 |
University Of Massachusetts |
Compositions and their uses for lysosomal enzyme deficiencies
|
|
JP2008514709A
(ja)
*
|
2004-10-01 |
2008-05-08 |
メルク エンド カムパニー インコーポレーテッド |
眼科疾患を治療するための組成物および方法
|
|
EP1647549A1
(en)
*
|
2004-10-14 |
2006-04-19 |
Laboratoire Theramex |
Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
|
|
US7612082B2
(en)
*
|
2004-10-28 |
2009-11-03 |
Allergan, Inc. |
Prostaglandin EP4 antagonists
|
|
US7101906B2
(en)
*
|
2004-11-16 |
2006-09-05 |
Allergan, Inc. |
2,3,4-substituted cyclopentanones as therapeutic agents
|
|
US7183324B2
(en)
|
2004-11-23 |
2007-02-27 |
Allergan, Inc. |
2,3,4-substituted cyclopentanones as therapeutic agents
|
|
BRPI0518798A2
(pt)
|
2004-12-03 |
2008-12-09 |
Transtech Pharma Inc |
composto, composiÇço farmacÊutica, e, mÉtodos para tratar diabete tipo ii e para tratar uma condiÇço ou distérbio
|
|
US7091231B2
(en)
*
|
2004-12-10 |
2006-08-15 |
Allergan, Inc. |
12-Aryl prostaglandin analogs
|
|
JP2008526861A
(ja)
*
|
2005-01-06 |
2008-07-24 |
メルク エンド カムパニー インコーポレーテッド |
炎症性障害を治療するための薬剤併用療法および医薬組成物
|
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
|
US7622583B2
(en)
|
2005-01-14 |
2009-11-24 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2
|
|
CA2594726C
(en)
|
2005-01-14 |
2013-03-19 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and ccr2
|
|
TWI386208B
(zh)
*
|
2005-04-18 |
2013-02-21 |
Allergan Inc |
治療性的經取代環戊酮
|
|
AU2006238855B2
(en)
*
|
2005-04-21 |
2011-12-22 |
Chemocentryx, Inc. |
Reagents that bind CCX-CKR2
|
|
CA2605228A1
(en)
|
2005-04-27 |
2007-03-08 |
Arena Pharmaceuticals, Inc. |
Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
|
|
US8420628B2
(en)
*
|
2005-05-06 |
2013-04-16 |
Allergan, Inc. |
Substituted beta-lactams
|
|
EP1721615A1
(en)
|
2005-05-09 |
2006-11-15 |
Komipharm International Co., Ltd. |
Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
|
|
CA2609402C
(en)
|
2005-05-23 |
2014-10-21 |
Sdg, Inc. |
Lipid construct for delivery of insulin to a mammal
|
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US7491732B2
(en)
|
2005-06-08 |
2009-02-17 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
|
US20070021357A1
(en)
*
|
2005-06-17 |
2007-01-25 |
Dynamis Therapeutics, Inc. |
Treatment of inflammatory conditions
|
|
US7777035B2
(en)
|
2005-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
|
WO2007002701A2
(en)
|
2005-06-27 |
2007-01-04 |
Amgen Inc. |
Anti-inflammatory aryl nitrile compounds
|
|
WO2007005176A1
(en)
*
|
2005-06-29 |
2007-01-11 |
Allergan, Inc. |
Pyrrolidinones for the treatment of glaucoma and ocular hypertension
|
|
US7884210B2
(en)
|
2005-07-14 |
2011-02-08 |
Novo Nordisk A/S |
Ureido-thiazole glucokinase activators
|
|
CN103784960A
(zh)
*
|
2005-07-27 |
2014-05-14 |
阿尔卡米亚肿瘤学股份有限公司 |
使用乙酰透明质酸的治疗方案
|
|
EP1948638B1
(en)
|
2005-08-12 |
2011-08-03 |
Schering Corporation |
Compounds for the treatment of inflammatory disorders
|
|
WO2007025166A2
(en)
|
2005-08-25 |
2007-03-01 |
Repair Technologies, Inc. |
Devices, compositions and methods for the protection and repair of cells and tissues
|
|
DK1919867T3
(da)
|
2005-08-29 |
2011-12-12 |
Univ Virginia Patent Found |
Lisofyllinanaloger og farmaceutiske anvendelser heraf
|
|
US8871764B2
(en)
|
2005-08-29 |
2014-10-28 |
University Of Virginia Patent Foundation |
Lisofylline analogs and methods for use
|
|
CN101287475B
(zh)
|
2005-09-07 |
2012-11-14 |
阿尔卡米亚肿瘤学股份有限公司 |
包含透明质酸和治疗抗体的治疗组合物以及制药用途
|
|
US20070178141A1
(en)
*
|
2005-09-07 |
2007-08-02 |
Bebaas, Inc. |
Vitamin B12 compositions
|
|
US20130131007A1
(en)
|
2005-09-07 |
2013-05-23 |
Bebaas, Inc. |
Vitamin b12 compositions
|
|
ATE526991T1
(de)
*
|
2005-10-24 |
2011-10-15 |
Univ Massachusetts |
Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
|
|
AU2006311577B2
(en)
|
2005-11-09 |
2013-02-07 |
Zalicus Inc. |
Methods, compositions, and kits for the treatment of medical conditions
|
|
WO2007059108A2
(en)
|
2005-11-10 |
2007-05-24 |
Chemocentryx, Inc. |
Substituted quinolones and methods of use
|
|
US7427685B2
(en)
|
2005-12-06 |
2008-09-23 |
Allergan, Inc. |
Therapeutic substituted cyclopentanes
|
|
US7585895B2
(en)
*
|
2005-12-06 |
2009-09-08 |
Allergan, Inc. |
Therapeutic substituted cyclopentanes
|
|
US20090306373A1
(en)
*
|
2005-12-20 |
2009-12-10 |
Gamber Gabriel G |
4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
|
|
US7323477B2
(en)
*
|
2006-02-02 |
2008-01-29 |
Allergan, Inc. |
7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
|
|
WO2007098240A2
(en)
*
|
2006-02-21 |
2007-08-30 |
Astrum Therapeutics Pty. Ltd. |
Compositions to reduce blood glucose levels and treat diabetes
|
|
CA2642229C
(en)
|
2006-02-24 |
2015-05-12 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
EP1864692A1
(en)
*
|
2006-06-07 |
2007-12-12 |
Biotempt B.V. |
Use of peptides for the control of radiation injury
|
|
AU2007226957B2
(en)
|
2006-03-20 |
2013-08-15 |
Allergan, Inc. |
Substituted gamma lactams as prostaglandin EP2 agonists
|
|
US20070225246A1
(en)
*
|
2006-03-27 |
2007-09-27 |
Denu John M |
O-acetyl-ADP-ribose non-hydrolyzable analogs
|
|
WO2007120689A2
(en)
|
2006-04-11 |
2007-10-25 |
Arena Pharmaceuticals, Inc. |
Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
|
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
WO2007118276A1
(en)
|
2006-04-14 |
2007-10-25 |
Prana Biotechnology Ltd |
Method of treatment of age-related macular degeneration(amd)
|
|
US7439372B2
(en)
|
2006-05-03 |
2008-10-21 |
Allergan, Inc. |
Therapeutic compounds
|
|
US20090016981A1
(en)
|
2006-05-03 |
2009-01-15 |
Allergan, Inc. |
Therapeutic compounds
|
|
US7476755B2
(en)
|
2006-05-04 |
2009-01-13 |
Allergan, Inc. |
Therapeutic compounds
|
|
MX2008014353A
(es)
|
2006-05-09 |
2008-11-24 |
Merck & Co Inc |
Antagonistas de los receptores del peptido relacionado con el gen de calcitonina (cgrp) monociclicos sustituidos.
|
|
US7547727B2
(en)
|
2006-05-22 |
2009-06-16 |
Allergan, Inc. |
Therapeutic cyclopentane derivatives
|
|
US7550448B2
(en)
*
|
2006-05-24 |
2009-06-23 |
Allergan, Inc. |
Therapeutic compounds
|
|
US7553860B2
(en)
*
|
2006-06-14 |
2009-06-30 |
Allergan, Inc. |
Substituted gamma lactams as therapeutic agents
|
|
CN103483260B
(zh)
|
2006-07-05 |
2016-08-03 |
梅瑞尔公司 |
1-芳基-5-烷基吡唑衍生化合物、其制备方法和使用方法
|
|
WO2008008701A2
(en)
|
2006-07-10 |
2008-01-17 |
Allergan, Inc. |
Substituted cyclopentane derivatives as therapeutic agents
|
|
NZ574759A
(en)
|
2006-07-14 |
2010-10-29 |
Chemocentryx Inc |
Triazolyl phenyl benzenesulfonamides
|
|
US8519135B2
(en)
*
|
2006-07-14 |
2013-08-27 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2/CCR9
|
|
US7700627B2
(en)
*
|
2006-07-26 |
2010-04-20 |
Allergan, Inc. |
Therapeutic substituted lactams
|
|
AU2007281220B2
(en)
|
2006-07-31 |
2013-08-15 |
Activesite Pharmaceuticals, Inc. |
Inhibitors of plasma kallikrein
|
|
WO2009137544A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Allergan, Inc. |
Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds
|
|
US7985767B2
(en)
*
|
2006-09-06 |
2011-07-26 |
Allergan, Inc. |
Therapeutic amides
|
|
AU2007292816B2
(en)
|
2006-09-07 |
2011-11-17 |
Amgen Inc. |
Benzo-fused compounds for use in treating metabolic disorders
|
|
EP2076525A2
(en)
*
|
2006-10-06 |
2009-07-08 |
Wisconsin Alumni Research Foundation |
Colchicine neoglycosides and methods for their synthesis and use
|
|
US8022061B2
(en)
|
2006-10-10 |
2011-09-20 |
Amgen Inc. |
N-aryl pyrazole compounds, compositions, and methods for their use
|
|
EP1920782A1
(en)
|
2006-11-10 |
2008-05-14 |
Glycotope Gmbh |
Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
|
|
WO2008073752A2
(en)
|
2006-12-11 |
2008-06-19 |
Allergan, Inc. |
Cyclobutyl derivatives for the treatment of glaucoma
|
|
GB0624757D0
(en)
|
2006-12-12 |
2007-01-17 |
Sosei R & D Ltd |
Novel compounds
|
|
EP2124909A4
(en)
|
2006-12-19 |
2010-03-31 |
Univ Virginia |
COMBINED EFFECTS OF TOPIRAMATE AND ONDANSETRON ON ALCOHOLIC BEVERAGE
|
|
US20080153881A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
|
|
US20080153825A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan Inc. |
Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
|
|
AU2007337097A1
(en)
|
2006-12-22 |
2008-07-03 |
Allergan, Inc. |
Alpha-2B adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
|
|
US20120083508A1
(en)
|
2006-12-22 |
2012-04-05 |
Allergan, Inc. |
Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
|
|
US20080153808A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
|
|
US20080153874A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan Inc. |
Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
|
|
US20080153832A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
|
|
US20080153927A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
|
|
US20080153880A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
|
|
US20100011786A1
(en)
*
|
2006-12-28 |
2010-01-21 |
Lg Electronics Inc. |
Ice making system and method for ice making of refrigerator
|
|
JP5226008B2
(ja)
|
2007-01-11 |
2013-07-03 |
ノボ・ノルデイスク・エー／エス |
ウレアグルコキナーゼアクチベーター
|
|
US20100221336A1
(en)
*
|
2007-02-14 |
2010-09-02 |
Logical Therapeutics, Inc. |
Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
|
|
CA2679301C
(en)
|
2007-02-28 |
2015-08-11 |
University Of Virginia Patent Foundation |
Lisofylline analogs and methods for use in protecting pancreatic .beta.-cells, treating type 1 diabetes, and treating inflammatory and autoimmune diseases
|
|
WO2008141013A1
(en)
*
|
2007-05-08 |
2008-11-20 |
Allergan, Inc. |
S1p3 receptor inhibitors for treating pain
|
|
SI3428148T1
(sl)
|
2007-05-15 |
2021-04-30 |
Boehringer Ingelheim Animal Health USA Inc. |
Ariloazol-2-il cianoetilamino spojine, postopek njihove izdelave in postopek njihove uporabe
|
|
JP5457338B2
(ja)
|
2007-05-22 |
2014-04-02 |
ケモセントリックス，インコーポレイティド |
３−（イミダゾリル）−ピラゾロ［３，４−ｂ］ピリジン
|
|
WO2008156721A1
(en)
|
2007-06-20 |
2008-12-24 |
Merck & Co., Inc. |
Diphenyl substituted alkanes
|
|
US7776877B2
(en)
|
2007-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
|
|
US7884110B2
(en)
|
2007-07-12 |
2011-02-08 |
Chemocentryx, Inc. |
Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
|
|
WO2009012425A2
(en)
*
|
2007-07-19 |
2009-01-22 |
Logigal Therapeutics, Inc. |
Compositions including leukotriene antagonists and nsaids and methods of using the same
|
|
EP2183227B1
(en)
|
2007-08-07 |
2014-09-24 |
Prosarix Limited |
1,2,4-triazole derivatives as serotonergic modulators
|
|
US8846053B2
(en)
|
2008-09-26 |
2014-09-30 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
|
US8962015B2
(en)
|
2007-09-28 |
2015-02-24 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
|
US8779002B2
(en)
|
2007-10-15 |
2014-07-15 |
Salk Institute For Biological Studies |
Methods for treating a variety of diseases and conditions, and compounds useful therefor
|
|
WO2009052073A2
(en)
*
|
2007-10-18 |
2009-04-23 |
Allergan, Inc. |
Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
|
|
WO2009052075A2
(en)
*
|
2007-10-18 |
2009-04-23 |
Allergan, Inc. |
Method of treating motor disorders with alpha-2b adrenergic receptor agonists
|
|
WO2009052072A1
(en)
*
|
2007-10-18 |
2009-04-23 |
Allergan, Inc. |
Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
|
|
JP2011517279A
(ja)
*
|
2007-10-29 |
2011-06-02 |
ユニバーシティ オブ マサチューセッツ |
核酸（ｓｉＲＮＡ）送達用の酵母細胞壁粒子（ＹＣＷＰ）多層状ナノ粒子
|
|
US8063033B2
(en)
|
2008-01-18 |
2011-11-22 |
Allergan, Inc. |
Therapeutic beta-lactams
|
|
US7956051B2
(en)
*
|
2008-01-24 |
2011-06-07 |
Allergan, Inc. |
Therapeutic amides and related compounds
|
|
US8633310B2
(en)
*
|
2008-02-19 |
2014-01-21 |
Allergan, Inc. |
Therapeutic substituted lactams
|
|
US8202855B2
(en)
|
2008-03-04 |
2012-06-19 |
Allergan, Inc |
Substituted beta-lactams
|
|
US7964596B2
(en)
*
|
2008-03-07 |
2011-06-21 |
Allergan, Inc. |
Therapeutic compounds
|
|
US20090233921A1
(en)
*
|
2008-03-11 |
2009-09-17 |
Allergan, Inc. |
Therapeutic cyclopentane derivatives
|
|
US7960379B2
(en)
*
|
2008-03-14 |
2011-06-14 |
Allergan, Inc. |
Therapeutic compounds
|
|
US20110009453A1
(en)
*
|
2008-03-17 |
2011-01-13 |
Donello John E |
s1p3 receptor inhibitors for treating inflammation
|
|
US7732443B2
(en)
*
|
2008-03-18 |
2010-06-08 |
Yariv Donde |
Therapeutic substituted cyclopentanes
|
|
US7960378B2
(en)
*
|
2008-03-18 |
2011-06-14 |
Allergan, Inc. |
Therapeutic compounds
|
|
US7705001B2
(en)
*
|
2008-03-18 |
2010-04-27 |
Allergan, Inc |
Therapeutic substituted gamma lactams
|
|
US8198318B2
(en)
*
|
2008-03-18 |
2012-06-12 |
Allergen, Inc. |
Therapeutic amides
|
|
US7956055B2
(en)
*
|
2008-03-25 |
2011-06-07 |
Allergan, Inc. |
Substituted gamma lactams as therapeutic agents
|
|
EP2146210A1
(en)
*
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
|
WO2009131958A2
(en)
*
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising triazine derivatives
|
|
WO2009131947A2
(en)
*
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising pyridazine derivatives
|
|
US8207205B2
(en)
|
2008-04-21 |
2012-06-26 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising oxadiazole derivatives
|
|
WO2009131951A2
(en)
*
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising isoxazole derivatives
|
|
CA2722529A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Allergan, Inc. |
Substituted gamma lactams as therapeutic agents
|
|
CA2731279A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Allergan, Inc. |
Therapeutic compounds
|
|
JP2011518834A
(ja)
|
2008-04-24 |
2011-06-30 |
アラーガン インコーポレイテッド |
治療剤としての置換ガンマラクタム
|
|
US7737140B2
(en)
*
|
2008-04-24 |
2010-06-15 |
Allergan, Inc. |
Therapeutic compounds
|
|
US7964634B2
(en)
*
|
2008-04-24 |
2011-06-21 |
Allergan, Inc. |
Therapeutic compounds
|
|
KR20110028584A
(ko)
*
|
2008-05-09 |
2011-03-21 |
알러간, 인코포레이티드 |
치료학적인 ｎ-아릴 또는 ｎ-헤테로아릴 피라졸리딘 및 피라졸리딘온 유도체
|
|
WO2009137411A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Allergan, Inc. |
Therapeutic compounds
|
|
WO2009137412A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Allergan, Inc. |
Therapeutic compounds
|
|
WO2009137343A1
(en)
|
2008-05-09 |
2009-11-12 |
Allergan, Inc. |
Therapeutic substituted hydantoins, and related compounds
|
|
CN102083807A
(zh)
*
|
2008-05-09 |
2011-06-01 |
阿勒根公司 |
治疗用化合物
|
|
CA2728227A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Allergan, Inc. |
Therapeutic cyclopentane derivatives
|
|
AU2009251474B2
(en)
*
|
2008-05-15 |
2014-06-05 |
Allergan, Inc. |
Prostaglandin prodrugs as hypotensive agents
|
|
WO2009142969A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Allergan, Inc. |
Therapeutic lactams
|
|
DK2291353T3
(da)
*
|
2008-05-20 |
2013-12-02 |
Allergan Inc |
Terapeutiske prostaglandinforbindelser anvendt som okulære hypotensive midler
|
|
CA2727243A1
(en)
|
2008-06-12 |
2009-12-17 |
Merck Sharp & Dohme Corp. |
Branched 3- and 6-substituted quinolines as cgrp receptor antagonists
|
|
WO2010012650A1
(en)
|
2008-07-28 |
2010-02-04 |
Syddansk Universitet |
Compounds for the treatment of metabolic diseases
|
|
US20100022574A1
(en)
*
|
2008-07-28 |
2010-01-28 |
EndogenX, Inc. |
Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
|
|
US8404736B2
(en)
|
2008-08-14 |
2013-03-26 |
Beta Pharma Canada Inc. |
Heterocyclic amide derivatives as EP4 receptor antagonists
|
|
JP2012503005A
(ja)
*
|
2008-09-19 |
2012-02-02 |
インスティテュート フォア ワンワールド ヘルス |
イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
|
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
|
EP2186521A1
(en)
|
2008-11-14 |
2010-05-19 |
Mergemeier Steffen |
Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
|
|
CA2945453C
(en)
|
2008-11-14 |
2021-03-02 |
Merial, Inc. |
Enantiomerically enriched aryloazol-2-yl cyanoethylamino paraciticidal compounds
|
|
AP3359A
(en)
|
2008-11-19 |
2015-07-31 |
Merial Ltd |
Compositions comprising 1-arylpyrazole alone or incombination with formamidine for the treatment of parasitic infection
|
|
KR20110088575A
(ko)
|
2008-11-21 |
2011-08-03 |
하이 포인트 파마슈티칼스, 엘엘씨 |
아다만틸 벤즈아미드 화합물
|
|
AU2009322206B2
(en)
|
2008-12-04 |
2015-03-05 |
Boehringer Ingelheim Animal Health USA Inc. |
Dimeric avermectin and milbemycin derivatives
|
|
TWI465434B
(zh)
|
2008-12-22 |
2014-12-21 |
Chemocentryx Inc |
Ｃ５ａＲ拮抗劑
|
|
EA022802B1
(ru)
|
2009-01-23 |
2016-03-31 |
Райджел Фармасьютикалз, Инк. |
Соединения, композиции и способы для лечения заболеваний, опосредованных jak-киназой
|
|
WO2010093910A1
(en)
|
2009-02-13 |
2010-08-19 |
Allergan, Inc. |
4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione
|
|
WO2010093849A2
(en)
|
2009-02-13 |
2010-08-19 |
Amgen Inc. |
Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
|
|
DK3566703T3
(da)
|
2009-02-13 |
2021-07-05 |
Allergan Inc |
Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
|
|
WO2010099039A1
(en)
|
2009-02-24 |
2010-09-02 |
Merck Sharp & Dohme Corp. |
Indole derivatives as crth2 receptor antagonists
|
|
GB0904044D0
(en)
|
2009-03-09 |
2009-04-22 |
Sosei R & D Ltd |
The treatment of inflammatory disorders and pain
|
|
EP2406282A1
(en)
|
2009-03-11 |
2012-01-18 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
US8511216B2
(en)
*
|
2009-03-30 |
2013-08-20 |
Kanzaki Kokyukoki Mfg. Co., Ltd. |
Hydraulic actuator unit
|
|
AU2010232556A1
(en)
|
2009-04-02 |
2011-11-03 |
Allergan, Inc. |
Prostaglandin E receptor antagonists
|
|
US8343976B2
(en)
*
|
2009-04-20 |
2013-01-01 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising pyrazole derivatives
|
|
CA3031836A1
(en)
|
2009-05-05 |
2010-11-11 |
Board Of Regents, The University Of Texas System |
Formulations of volatile anesthetics for reducing inflammation
|
|
AU2010250766B2
(en)
|
2009-05-19 |
2015-04-09 |
Neuroderm Ltd |
Compositions for continuous administration of dopa decarboxylase inhibitors
|
|
WO2011009061A1
(en)
|
2009-07-17 |
2011-01-20 |
Allergan, Inc. |
Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
|
|
RU2557982C2
(ru)
*
|
2009-07-28 |
2015-07-27 |
Райджел Фармасьютикалз, Инк. |
Композиции и способы ингибирования пути jak
|
|
WO2011019678A1
(en)
|
2009-08-11 |
2011-02-17 |
Allergan, Inc. |
Isothiozoles for treating conditions of the eye
|
|
US20110045522A1
(en)
*
|
2009-08-20 |
2011-02-24 |
Danchen Gao |
Methods for diagnosing diabetes and determining effectiveness of treatments
|
|
CA2772354A1
(en)
|
2009-08-26 |
2011-03-10 |
Daniel W. Gil |
Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists
|
|
IN2012DN00721A
(es)
|
2009-09-02 |
2015-06-19 |
Merck Sharp & Dohme |
|
|
US9889182B2
(en)
|
2009-09-15 |
2018-02-13 |
The Regents Of The University Of California |
Assisted enzyme replacement therapy
|
|
EP2480531B1
(en)
|
2009-09-21 |
2014-11-05 |
ChemoCentryx, Inc. |
Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators
|
|
WO2011041198A1
(en)
|
2009-09-30 |
2011-04-07 |
Transtech Pharma, Inc. |
Substituted imidazole derivatives for treatment of alzheimers disease
|
|
EP2504311B1
(en)
|
2009-11-25 |
2015-08-12 |
Cytometix, Inc. |
Arachidonic acid analogs and methods for analgesic treatment using same
|
|
AU2010325827B2
(en)
|
2009-12-04 |
2015-11-05 |
Basf Se |
Pesticidal bis-organosulfur compounds
|
|
PL3078664T3
(pl)
|
2009-12-17 |
2019-08-30 |
Merial Inc. |
Dihydroazolowe kompozycje przeciwpasożytnicze
|
|
US8980896B2
(en)
|
2009-12-17 |
2015-03-17 |
Merial, Inc. |
Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
|
|
WO2011079778A1
(en)
*
|
2009-12-30 |
2011-07-07 |
China Shanghai Fochon Pharmaceutical Co Ltd |
3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
|
US9090584B2
(en)
|
2010-01-26 |
2015-07-28 |
Allergan, Inc. |
Therapeutic agents for treatment of ocular hypertension
|
|
AU2011210352A1
(en)
|
2010-01-26 |
2012-08-09 |
Radikal Therapeutics Inc. |
Compositions and methods for prevention and treatment of pulmonary hypertension
|
|
US8299068B2
(en)
*
|
2010-01-29 |
2012-10-30 |
Allergan, Inc. |
Therapeutically active cyclopentanes
|
|
HUE044221T2
(hu)
|
2010-02-03 |
2019-10-28 |
Pharma Two B Ltd |
Nyújtott hatóanyagleadású razagilin készítmények és alkalmazásaik
|
|
GB201002530D0
(en)
|
2010-02-15 |
2010-03-31 |
Univ Wolverhampton The |
Di-aspirin derivatives
|
|
TWI510241B
(zh)
|
2010-02-18 |
2015-12-01 |
Vtv Therapeutice Llc |
苯基－雜芳基衍生物及其使用方法
|
|
CN102762101B
(zh)
|
2010-02-18 |
2014-09-17 |
高点制药有限责任公司 |
取代的稠合咪唑衍生物、药物组合物及其使用方法
|
|
US8853212B2
(en)
|
2010-02-22 |
2014-10-07 |
Merck Sharp & Dohme Corp |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
|
|
KR102113960B1
(ko)
|
2010-03-30 |
2020-05-21 |
베르선 코포레이션 |
트롬빈 억제제로서의 다중치환된 방향족 화합물
|
|
UA108641C2
(uk)
|
2010-04-02 |
2015-05-25 |
|
Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
|
|
WO2011130716A2
(en)
|
2010-04-16 |
2011-10-20 |
Access Pharmaceuticals, Inc. |
A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
|
|
US20110288103A1
(en)
|
2010-04-20 |
2011-11-24 |
Institute For Oneworld Health |
Compounds, compositions, and methods comprising 1,3,4-oxadiazole derivatives
|
|
WO2011133600A1
(en)
|
2010-04-20 |
2011-10-27 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
|
|
WO2011141909A2
(en)
|
2010-05-10 |
2011-11-17 |
Radikal Therapeutics Inc. |
Lipoic acid and nitroxide derivatives and uses thereof
|
|
US8980929B2
(en)
|
2010-05-21 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
|
NZ603614A
(en)
|
2010-05-26 |
2014-10-31 |
Transtech Pharma Llc |
Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
|
|
ES2664872T3
(es)
|
2010-06-18 |
2018-04-23 |
Taiho Pharmaceutical Co., Ltd |
Moduladores PRPK-TPRKB y sus usos
|
|
AU2011270872A1
(en)
|
2010-06-24 |
2013-01-31 |
Allergan, Inc. |
Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
|
|
CN103068385B
(zh)
|
2010-06-24 |
2015-04-29 |
凯莫森特里克斯股份有限公司 |
C5aR拮抗剂
|
|
US8859606B2
(en)
|
2010-07-01 |
2014-10-14 |
Allergan, Inc. |
Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
US8492424B2
(en)
|
2010-07-01 |
2013-07-23 |
Allergan, Inc. |
Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
US9714238B2
(en)
|
2010-07-02 |
2017-07-25 |
Allergan, Inc. |
Therapeutic agents for ocular hypertension
|
|
UA116615C2
(uk)
|
2010-07-02 |
2018-04-25 |
Юніверсіті Оф Вірджінія Петент Фаундейшн |
Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем
|
|
WO2012003145A2
(en)
|
2010-07-02 |
2012-01-05 |
Allergan, Inc. |
Therapeutic agents for ocular hypertension
|
|
EP2598500B1
(en)
|
2010-07-28 |
2021-05-19 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US20130303497A1
(en)
|
2010-08-05 |
2013-11-14 |
Conrig Pharma Aps |
Deuterated 5-ht1a receptor agonists
|
|
CN114073696A
(zh)
|
2010-08-16 |
2022-02-22 |
阿勒根公司 |
用α-2B肾上腺素能受体激动剂活化调节T细胞的方法
|
|
US20120077858A1
(en)
|
2010-08-20 |
2012-03-29 |
Allergan, Inc. |
Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
WO2012032513A1
(en)
|
2010-09-07 |
2012-03-15 |
Bar-Ilan University |
Boranophosphate derivatives for the treatment of osteoarthritis
|
|
WO2012032524A1
(en)
|
2010-09-09 |
2012-03-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd |
Near infrared fluorescent particles and uses thereof
|
|
GB201016880D0
(en)
|
2010-10-07 |
2010-11-17 |
Riotech Pharmaceuticals Ltd |
Phosphodiesterase inhibitors
|
|
MX353625B
(es)
|
2010-10-15 |
2018-01-22 |
Contera Pharma Aps |
Combinaciones de agonistas del receptor de serotonina para el tratamiento de trastornos de movimiento.
|
|
US20130315934A1
(en)
|
2010-10-28 |
2013-11-28 |
Yale University |
Methods and Compositions for Assessing and Treating Cancer
|
|
WO2012059932A1
(en)
|
2010-11-01 |
2012-05-10 |
Aurigene Discovery Technologies Limited |
2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
|
|
TWI522355B
(zh)
|
2010-11-12 |
2016-02-21 |
默沙東藥廠 |
六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
|
|
PT2640358T
(pt)
|
2010-11-15 |
2018-02-23 |
Neuroderm Ltd |
Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos
|
|
LT2640728T
(lt)
|
2010-11-16 |
2017-03-27 |
Merial, Inc. |
Nauji monenzino dariniai, skirti pirmuonių sukeltų infekcijų gydymui
|
|
WO2012071525A2
(en)
|
2010-11-24 |
2012-05-31 |
Yale University |
Compositions and methods for diagnosing and treating diseases and disorders associated with d-dt
|
|
US20130296331A1
(en)
|
2010-11-26 |
2013-11-07 |
Technion Research And Development Foundation Ltd. |
Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
|
|
AU2011336973A1
(en)
|
2010-12-03 |
2013-07-11 |
Allergan, Inc. |
Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
|
|
JP6076913B2
(ja)
|
2010-12-07 |
2017-02-08 |
ドレクセル ユニバーシティ |
癌からの転移を阻害する方法
|
|
GB201020860D0
(en)
|
2010-12-09 |
2011-01-26 |
Univ Wolverhampton |
Disulfiram formulation and uses thereof
|
|
BR112013014890B1
(pt)
|
2010-12-15 |
2023-10-24 |
Contravir Pharmaceuticals, Inc |
Composto análogo de moléculas pertencentes à família ciclosporina, composição farmacêutica compreendendo o mesmo, uso terapêutico ou profilático do referido composto e processos para a preparação dos mesmos
|
|
US8895572B2
(en)
|
2010-12-22 |
2014-11-25 |
Merck Sharp & Dohme Corp. |
Fused heterocyclic indane carboxamide CGRP receptor antagonists
|
|
WO2012093383A1
(en)
|
2011-01-04 |
2012-07-12 |
Radikal Therapeutics Inc. |
Compositions and methods for treatment of sepsis and related conditions
|
|
US11759441B2
(en)
|
2011-01-07 |
2023-09-19 |
Anji Pharmaceuticals Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
|
US11974971B2
(en)
|
2011-01-07 |
2024-05-07 |
Anji Pharmaceuticals Inc. |
Compositions and methods for treating metabolic disorders
|
|
US9211263B2
(en)
|
2012-01-06 |
2015-12-15 |
Elcelyx Therapeutics, Inc. |
Compositions and methods of treating metabolic disorders
|
|
WO2013103919A2
(en)
|
2012-01-06 |
2013-07-11 |
Elcelyx Therapeutics, Inc. |
Compositions and methods for treating metabolic disorders
|
|
US8796338B2
(en)
|
2011-01-07 |
2014-08-05 |
Elcelyx Therapeutics, Inc |
Biguanide compositions and methods of treating metabolic disorders
|
|
US9572784B2
(en)
|
2011-01-07 |
2017-02-21 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
|
KR20140035331A
(ko)
|
2011-01-07 |
2014-03-21 |
엘셀릭스 테라퓨틱스 인코포레이티드 |
화학감각 수용체 리간드-기반 요법
|
|
US9480663B2
(en)
|
2011-01-07 |
2016-11-01 |
Elcelyx Therapeutics, Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
|
US20120231069A1
(en)
|
2011-03-08 |
2012-09-13 |
Access Pharmaceuticals, Inc. |
Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes
|
|
ES2686532T3
(es)
|
2011-03-10 |
2018-10-18 |
Rigel Pharmaceuticals, Inc. |
2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide
|
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
|
EP2937349B1
(en)
|
2011-03-23 |
2016-12-28 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
|
GEP20166444B
(en)
|
2011-04-06 |
2016-03-10 |
Medical College Of Wisconsin |
Epoxyeicosatrienoic acid analogs and methods of making and using the same
|
|
EP2694465A4
(en)
|
2011-04-08 |
2015-03-18 |
Univ Syddansk |
SUBSTITUTED ORTHOFLUOR COMPOUNDS FOR THE TREATMENT OF METABOLISM DISEASES
|
|
EP2696897A2
(en)
|
2011-04-11 |
2014-02-19 |
Yeda Research and Development Co. Ltd. |
Albumin binding probes and drug conjugates thereof
|
|
US8691861B2
(en)
|
2011-04-13 |
2014-04-08 |
Activesite Pharmaceuticals, Inc. |
Prodrugs of inhibitors of plasma kallikrein
|
|
WO2012143377A1
(en)
|
2011-04-18 |
2012-10-26 |
Max-Delbrück-Centrum für Molekulare Medizin |
Niclosamide for the treatment of cancer metastasis
|
|
MX362218B
(es)
|
2011-05-04 |
2019-01-09 |
Balance Therapeutics Inc |
Derivados de pentilentetrazol.
|
|
CA2835203A1
(en)
|
2011-05-09 |
2012-11-15 |
University Of Virginia Patent Foundation |
Compositions and methods for treating cancer
|
|
US8735451B2
(en)
|
2011-05-27 |
2014-05-27 |
Allergan, Inc. |
D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders
|
|
WO2012163365A1
(en)
|
2011-06-01 |
2012-12-06 |
Concit Pharma Aps |
Combinations of serotonin receptor agonists for treatment of movement disorders
|
|
US20120329873A1
(en)
|
2011-06-17 |
2012-12-27 |
Li yong-xin |
D-serine for the treatment of visual system disorders
|
|
US20120329832A1
(en)
|
2011-06-27 |
2012-12-27 |
Jean Delaveau |
Novel Insect-Repellent Coumarin Derivatives, Syntheses, and Methods of Use
|
|
CA2840396C
(en)
|
2011-06-27 |
2020-07-14 |
Merial Limited |
Amido-pyridyl ether compounds and compositions and their use against parasites
|
|
WO2013005216A1
(en)
|
2011-07-05 |
2013-01-10 |
Radikal Therapeutics Inc. |
Compositions and methods for treatment of renal ischemia-reperfusion injury
|
|
MX336578B
(es)
|
2011-07-25 |
2016-01-25 |
Allergan Inc |
Derivados de n-(imidazolidin-2-ilideno)-heterociclopenta[b] pirididina como moduladores de receptores de alfa 2 adrenergicos.
|
|
US8609658B2
(en)
|
2011-07-27 |
2013-12-17 |
Allergan, Inc. |
N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
|
|
WO2013019169A1
(en)
|
2011-08-01 |
2013-02-07 |
Institute For Oneworld Health |
Phosphate prodrugs
|
|
WO2013036290A1
(en)
|
2011-09-09 |
2013-03-14 |
Yale University |
Compositions and methods for assessing and treating inflammatory diseases and disorders
|
|
EA027743B1
(ru)
|
2011-09-09 |
2017-08-31 |
Юниверсити Оф Вирджиния Пэтент Фаундейшн |
Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
|
|
US8962608B2
(en)
|
2011-09-22 |
2015-02-24 |
Merck Sharp & Dohme Corp. |
Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
|
|
EP2763535B1
(en)
|
2011-10-03 |
2017-06-07 |
Merck Sharp & Dohme Corp. |
Azaindoles as janus kinase inhibitors
|
|
AU2012332176B2
(en)
|
2011-11-03 |
2016-03-10 |
Tlc Biopharmaceuticals, Inc. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
|
US10980798B2
(en)
|
2011-11-03 |
2021-04-20 |
Taiwan Liposome Company, Ltd. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
|
JP6249568B2
(ja)
|
2011-11-17 |
2017-12-20 |
メリアル インコーポレイテッド |
アリールピラゾールと置換イミダゾールを含む組成物、その使用方法
|
|
US9713605B2
(en)
|
2011-11-18 |
2017-07-25 |
Simpson Biotech Co., Ltd. |
Ameliorative or preventive effect of Antrodia cinnamomea in arthritis, cartilage destruction, or chondrocyte death
|
|
CA2856507C
(en)
|
2011-11-21 |
2017-03-21 |
Allergan, Inc. |
Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
|
|
BR112014013150A2
(pt)
|
2011-12-01 |
2017-06-13 |
Chemocentryx Inc |
benzimidazoles e benzopirazoles substituídas como antagonistas de ccr(4)
|
|
JP6141864B2
(ja)
|
2011-12-01 |
2017-06-07 |
ケモセントリックス，インコーポレイティド |
Ｃｃｒ（４）アンタゴニストとしての置換アニリン
|
|
WO2013082373A1
(en)
|
2011-12-02 |
2013-06-06 |
Merial Limited |
Long-acting injectable moxidectin formulations and novel moxidectin crystal forms
|
|
WO2013085802A1
(en)
|
2011-12-06 |
2013-06-13 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
|
AU2012358983B2
(en)
|
2011-12-21 |
2017-09-14 |
Allergan, Inc. |
Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
WO2013096496A2
(en)
|
2011-12-21 |
2013-06-27 |
Allergan, Inc. |
Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
EP2797894A1
(en)
|
2011-12-27 |
2014-11-05 |
Allergan, Inc. |
Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
AU2012362724C1
(en)
|
2011-12-27 |
2018-01-18 |
Allergan, Inc. |
Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
EP2800561B1
(en)
|
2012-01-06 |
2020-08-19 |
Anji Pharma (US) LLC |
Biguanide compositions and methods of treating metabolic disorders
|
|
WO2013122920A1
(en)
|
2012-02-17 |
2013-08-22 |
Merck Sharp & Dohme Corp. |
Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
MX2014010340A
(es)
|
2012-02-29 |
2015-02-24 |
Chemocentryx Inc |
Sulfonamidas de aza-aril 1h-pirazol-1-il benceno.
|
|
CA2865504A1
(en)
|
2012-03-23 |
2013-09-26 |
Oxigene, Inc. |
Compositions and methods for inhibition of cathepsins
|
|
WO2013151982A1
(en)
|
2012-04-03 |
2013-10-10 |
Arena Pharmaceuticals, Inc. |
Methods and compounds useful in treating pruritus, and methods for identifying such compounds
|
|
WO2013155600A1
(en)
|
2012-04-16 |
2013-10-24 |
Kaneq Pharma |
Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
|
|
US9388127B2
(en)
|
2012-04-17 |
2016-07-12 |
University College Dublin, National University Of Ireland, Dublin |
Thromboxane receptor antagonists
|
|
WO2013156861A2
(en)
|
2012-04-17 |
2013-10-24 |
University College Dublin, National University Of Ireland, Dublin |
Methods and compounds for treating proliferative disorders and viral infections
|
|
NZ700474A
(en)
|
2012-04-18 |
2016-10-28 |
Contera Pharma Aps |
Orally available pharmaceutical formulation suitable for improved management of movement disorders
|
|
WO2013169574A2
(en)
|
2012-05-09 |
2013-11-14 |
Merck Sharp & Dohme Corp. |
Aliphatic spirolactam cgrp receptor antagonists
|
|
US9296750B2
(en)
|
2012-05-09 |
2016-03-29 |
Merck Sharp & Dohme Corp. |
Spirolactam CGRP receptor antagonists
|
|
EP2846801B1
(en)
|
2012-05-09 |
2017-04-05 |
Merck Sharp & Dohme Corp. |
Pyridine cgrp receptor antagonists
|
|
WO2013173506A2
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
|
US20150368197A1
(en)
|
2012-06-21 |
2015-12-24 |
Radikal Therapeutics Ins. |
Compositions and methods for treatment of inflammatory diseases of the lung
|
|
WO2014018350A1
(en)
|
2012-07-23 |
2014-01-30 |
Merck Sharp & Dohme Corp. |
Treating diabetes with dipeptidyl peptidase-iv inhibitors
|
|
US20140024621A1
(en)
|
2012-07-23 |
2014-01-23 |
Ms Therapeutics Limited |
Aminopyridine compounds and their uses
|
|
ES2689906T3
(es)
|
2012-08-09 |
2018-11-16 |
Dynamis Therapeutics, Inc. |
Meglumina para reducir los niveles altos de triglicéridos
|
|
US9505749B2
(en)
|
2012-08-29 |
2016-11-29 |
Amgen Inc. |
Quinazolinone compounds and derivatives thereof
|
|
WO2014043257A1
(en)
|
2012-09-12 |
2014-03-20 |
Rigel Pharmaceuticals, Inc. |
Treatment for vitiligo
|
|
AU2013333765B2
(en)
|
2012-10-19 |
2017-12-07 |
Txp Pharma Gmbh |
Alpha- and gamma-MSH analogues
|
|
RU2661896C2
(ru)
|
2012-11-16 |
2018-07-23 |
Мерк Шарп И Доум Корп. |
Пуриновые ингибиторы фосфатидилинозитол-3-киназы дельта человека
|
|
EP3428162B1
(en)
|
2012-11-20 |
2021-05-05 |
Boehringer Ingelheim Animal Health USA Inc. |
Anthelmintic compounds and compositions and method of using thereof
|
|
ES2707323T3
(es)
|
2012-12-07 |
2019-04-03 |
Chemocentryx Inc |
Diazol lactamas
|
|
CA2894715C
(en)
|
2012-12-21 |
2021-06-15 |
Chemocentryx, Inc. |
Diazole amides
|
|
JP6403688B2
(ja)
|
2013-01-21 |
2018-10-10 |
アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ |
全身性抗炎症反応を提供する複数のプロスタグランジン受容体で作用する化合物
|
|
US20140213555A1
(en)
|
2013-01-25 |
2014-07-31 |
Rigel Pharmaceuticals, Inc. |
Compounds and method for treating autoimmune diseases
|
|
WO2014134774A1
(en)
|
2013-03-04 |
2014-09-12 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
|
RU2659220C2
(ru)
|
2013-03-05 |
2018-06-29 |
Зальцман Груп, Инк. |
Пролекарства многофункциональных производных нитроксида и их применение
|
|
HRP20211442T1
(hr)
|
2013-03-13 |
2022-02-04 |
Neuroderm Ltd |
Kombinacija za liječenje parkinsonove bolesti
|
|
EP3366668B1
(en)
|
2013-03-14 |
2023-06-21 |
Alkermes Pharma Ireland Limited |
Prodrugs of fumarates and their use in treating various deseases
|
|
SG10201707480PA
(en)
|
2013-03-15 |
2017-10-30 |
Verseon Corp |
Multisubstituted aromatic compounds as serine protease inhibitors
|
|
MX2015011567A
(es)
|
2013-03-15 |
2016-04-25 |
Verseon Corp |
Halogeno-pirazoles como inhibidores de trombina.
|
|
WO2014179263A1
(en)
|
2013-04-30 |
2014-11-06 |
Allergan, Inc. |
Therapeutic agents
|
|
WO2014194209A1
(en)
|
2013-05-31 |
2014-12-04 |
Allergan, Inc. |
Substituted cyclopentenes as therapeutic agents
|
|
CA2917149C
(en)
|
2013-07-02 |
2021-02-02 |
Cineole Corp., Llc |
Antimicrobial formulation comprising isoamyl hexanoates together with propanoic acid and/or isobutyric acid
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EP3035800B1
(en)
|
2013-08-22 |
2019-10-09 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
|
US9572760B2
(en)
|
2013-10-23 |
2017-02-21 |
Simpson Biotech Co., Ltd. |
Uses of compounds and mixtures from Antrodia cinnamomea mycelia
|
|
US9315486B2
(en)
|
2013-10-29 |
2016-04-19 |
Allergan, Inc. |
Therapeutic cyclopentanols, compositions thereof, and methods for use thereof
|
|
KR102341193B1
(ko)
|
2013-11-01 |
2021-12-17 |
뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 |
구충 및 살충성의 이속사졸린 화합물
|
|
WO2015073344A1
(en)
|
2013-11-14 |
2015-05-21 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
|
AU2014360743C1
(en)
|
2013-12-02 |
2021-01-28 |
Chemocentryx, Inc. |
CCR6 compounds
|
|
US9388153B2
(en)
|
2013-12-20 |
2016-07-12 |
Allergan, Inc. |
Secondary amines as therapeutic agents
|
|
CA2945687A1
(en)
|
2014-01-27 |
2015-07-30 |
Allergan, Inc. |
Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
|
|
CN112022818A
(zh)
|
2014-02-05 |
2020-12-04 |
默沙东公司 |
Cgrp-活性化合物的片剂制剂
|
|
US10258585B2
(en)
|
2014-03-13 |
2019-04-16 |
Neuroderm, Ltd. |
DOPA decarboxylase inhibitor compositions
|
|
HRP20231716T1
(hr)
|
2014-03-13 |
2024-03-15 |
Neuroderm Ltd. |
Pripravci inhibitora dopa dekarboksilaze
|
|
WO2015162483A1
(en)
|
2014-04-22 |
2015-10-29 |
Txp Pharma Gmbh |
Alpha- and gamma-msh analogues
|
|
WO2015162486A1
(en)
|
2014-04-22 |
2015-10-29 |
Txp Pharma Gmbh |
Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
|
|
AU2015249540B2
(en)
|
2014-04-22 |
2019-08-22 |
Txp Pharma Gmbh |
Peptide analogues with branched amino acid probe(s)
|
|
US9394273B2
(en)
|
2014-05-15 |
2016-07-19 |
Allergan, Inc. |
Therapeutic prostaglandin receptor agonists
|
|
US10045979B2
(en)
|
2014-05-19 |
2018-08-14 |
Merial Inc. |
Anthelmintic compounds
|
|
WO2015179815A1
(en)
|
2014-05-22 |
2015-11-26 |
Allergan, Inc. |
Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
|
|
KR101636758B1
(ko)
*
|
2014-05-30 |
2016-07-06 |
디씨에스이엔지 주식회사 |
회전속도비를 이용하여 회전체내 절삭툴을 제어할 수 있는 오비탈식 파이프 절삭장치
|
|
CA2953218A1
(en)
|
2014-06-06 |
2015-12-10 |
Allergan, Inc. |
Ep4 agonists as therapeutic compounds
|
|
US9908923B2
(en)
|
2014-06-11 |
2018-03-06 |
The Medical College Of Wisconsin, Inc. |
Monomeric CXCL121 peptide and methods of use thereof
|
|
WO2016009341A1
(en)
|
2014-07-14 |
2016-01-21 |
Radikal Therapeutics Inc. |
Thioredoxin mimetic prodrugs and uses thereof
|
|
GB201417828D0
(en)
|
2014-10-08 |
2014-11-19 |
Cereno Scient Ab |
New methods and compositions
|
|
US10954240B2
(en)
|
2014-09-03 |
2021-03-23 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
|
BR112017004704A2
(pt)
|
2014-09-17 |
2018-01-23 |
Verseon Corp |
composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
|
|
JP6954834B2
(ja)
|
2014-10-06 |
2021-10-27 |
ケモセントリックス，インコーポレイティド |
ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法
|
|
CN111961050A
(zh)
|
2014-12-02 |
2020-11-20 |
普拉纳生物技术有限公司 |
4H-吡啶并[1,2-a]嘧啶-4-酮化合物
|
|
DK3230255T3
(da)
|
2014-12-09 |
2020-06-22 |
Ezekiel Golan |
Regulatorer af uhæmmet adfærd
|
|
US10064936B2
(en)
|
2015-02-20 |
2018-09-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Mixed allergen compositions and methods for using the same
|
|
RU2017131562A
(ru)
|
2015-02-27 |
2019-03-27 |
Версеон Корпорейшн |
Замещенные пиразольные соединения как ингибиторы сериновых протеаз
|
|
SG11201707276PA
(en)
|
2015-03-09 |
2017-10-30 |
Intekrin Therapeutics Inc |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
|
WO2016187408A1
(en)
|
2015-05-19 |
2016-11-24 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
|
RU2707298C2
(ru)
|
2015-05-20 |
2019-11-26 |
Мериал, Инк. |
Противогельминтные депсипептидные соединения
|
|
KR102653667B1
(ko)
|
2015-05-20 |
2024-04-03 |
암젠 인크 |
Apj 수용체의 트라이아졸 작용제
|
|
US11571462B2
(en)
|
2015-06-03 |
2023-02-07 |
The Medical College Of Wisconsin, Inc. |
Engineered CCL20 locked dimer polypeptide
|
|
JP6786526B2
(ja)
|
2015-06-03 |
2020-11-18 |
ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． |
改変されたｃｃｌ２０ロックド二量体ポリペプチド
|
|
KR102240347B1
(ko)
|
2015-06-15 |
2021-04-15 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
노화와 연관된 질환을 치료하기 위한 방법 및 조성물
|
|
WO2016205334A1
(en)
|
2015-06-16 |
2016-12-22 |
Vascular Strategies Llc |
Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
|
|
DK3310756T3
(da)
|
2015-06-16 |
2021-03-08 |
Atxa Therapeutics Ltd |
Thromboxanreceptorantagonister
|
|
CA2990230A1
(en)
|
2015-06-19 |
2016-12-22 |
University Of Southern California |
Compositions and methods for modified nutrient delivery
|
|
US10744070B2
(en)
|
2015-06-19 |
2020-08-18 |
University Of Southern California |
Enteral fast access tract platform system
|
|
NO346258B1
(en)
|
2015-06-30 |
2022-05-16 |
Neurad Ltd |
Novel breathing control modulating compounds, and methods of making and using same
|
|
US11173197B2
(en)
|
2015-07-07 |
2021-11-16 |
Bluewillow Biologics, Inc. |
Methods and compositions for nanoemulsion vaccine formulations
|
|
EP3334706B1
(en)
|
2015-08-10 |
2020-09-30 |
Ramot at Tel-Aviv University Ltd. |
Pillararenes and uses thereof
|
|
CA3003741A1
(en)
|
2015-11-02 |
2017-05-11 |
University Of Rochester |
Bortezomib conjugates and methods using same
|
|
WO2017077528A2
(en)
|
2015-11-02 |
2017-05-11 |
Salzman Lovelace Investments, Ltd. |
Methods and pharmaceutical compositions for treatment of lung inflammation
|
|
WO2017079260A1
(en)
|
2015-11-02 |
2017-05-11 |
University Of Rochester |
Phosphonate-chloroquine conjugates and methods using same
|
|
TWI724056B
(zh)
|
2015-11-19 |
2021-04-11 |
美商卡默森屈有限公司 |
Ｃｘｃｒ２抑制劑
|
|
TWI734715B
(zh)
|
2015-11-19 |
2021-08-01 |
美商卡默森屈有限公司 |
趨化因子受體調節劑
|
|
JP2018537093A
(ja)
|
2015-11-20 |
2018-12-20 |
イエール ユニバーシティ |
異所性石灰化障害を治療するための組成物およびそれを使用する方法
|
|
BR112018014222A2
(pt)
|
2016-01-14 |
2018-12-11 |
Chemocentryx, Inc. |
método de tratamento da glomerulopatia c3
|
|
KR20180101565A
(ko)
|
2016-01-20 |
2018-09-12 |
케모센트릭스, 인크. |
2-옥신돌 화합물
|
|
CN108601750A
(zh)
|
2016-02-11 |
2018-09-28 |
莫迪凯·舍维龙 |
用于治疗神经变性的方法和药物组合物
|
|
UY37137A
(es)
|
2016-02-24 |
2017-09-29 |
Merial Inc |
Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
|
|
WO2017153977A1
(en)
|
2016-03-08 |
2017-09-14 |
Salzman Lovelace Investments, Ltd. |
Solid formulations of resolvins and uses thereof
|
|
EP3439658B1
(en)
|
2016-04-04 |
2021-11-24 |
ChemoCentryx, Inc. |
Soluble c5ar antagonists
|
|
WO2017177037A1
(en)
|
2016-04-06 |
2017-10-12 |
University Of Virginia Patent Foundation |
Compositions and methods for treating cancer
|
|
US9988369B2
(en)
|
2016-05-03 |
2018-06-05 |
Amgen Inc. |
Heterocyclic triazole compounds as agonists of the APJ receptor
|
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
|
CA3026434A1
(en)
|
2016-06-03 |
2017-12-07 |
Novacyte, Inc. |
Polymer linkers and their uses
|
|
US10036024B2
(en)
|
2016-06-03 |
2018-07-31 |
Purdue Research Foundation |
siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
|
|
CN109803651B
(zh)
|
2016-06-27 |
2022-05-31 |
凯莫森特里克斯股份有限公司 |
免疫调节剂化合物
|
|
CN109689036A
(zh)
|
2016-07-11 |
2019-04-26 |
康特拉医药公司 |
用于治疗早晨运动不能的脉冲药物输送***
|
|
WO2018026764A1
(en)
|
2016-08-01 |
2018-02-08 |
University Of Rochester |
Nanoparticles for controlled release of anti-biofilm agents and methods of use
|
|
WO2018039508A1
(en)
|
2016-08-25 |
2018-03-01 |
Merial, Inc. |
Method for reducing unwanted effects in parasiticidal treatments
|
|
US10449230B2
(en)
|
2016-10-06 |
2019-10-22 |
The Regents Of The University Of California |
Polymyxin derived cell penetrating scaffolds
|
|
BR112019007605A2
(pt)
|
2016-10-14 |
2019-09-17 |
Boehringer Ingelheim Animal Health Usa Inc |
compostos pesticidas e parasiticidas de vinil isoxazolina
|
|
CA3042671A1
(en)
|
2016-11-03 |
2018-05-11 |
Laurence I. Wu |
Prodrugs of clofarabine
|
|
EP3534903B1
(en)
|
2016-11-07 |
2022-08-03 |
Arbutus Biopharma Corporation |
Substituted pyridinone-containing tricyclic compounds, and methods using same
|
|
US10906890B2
(en)
|
2016-11-16 |
2021-02-02 |
Amgen Inc. |
Triazole phenyl compounds as agonists of the APJ receptor
|
|
WO2018097945A1
(en)
|
2016-11-16 |
2018-05-31 |
Amgen Inc. |
Heteroaryl-substituted triazoles as apj receptor agonists
|
|
US10736883B2
(en)
|
2016-11-16 |
2020-08-11 |
Amgen Inc. |
Triazole furan compounds as agonists of the APJ receptor
|
|
WO2018093580A1
(en)
|
2016-11-16 |
2018-05-24 |
Amgen Inc. |
Triazole pyridyl compounds as agonists of the apj receptor
|
|
EP3541804A1
(en)
|
2016-11-16 |
2019-09-25 |
Amgen Inc. |
Cycloalkyl substituted triazole compounds as agonists of the apj receptor
|
|
CA3044038A1
(en)
|
2016-11-16 |
2018-05-24 |
Boehringer Ingelheim Animal Health USA Inc. |
Anthelmintic depsipeptide compounds
|
|
EP3541802A1
(en)
|
2016-11-16 |
2019-09-25 |
Amgen Inc. |
Alkyl substituted triazole compounds as agonists of the apj receptor
|
|
MX2019005810A
(es)
|
2016-11-23 |
2019-09-11 |
Chemocentryx Inc |
Método para tratar glomeruloesclerosis segmentaria focal.
|
|
WO2018106928A1
(en)
|
2016-12-08 |
2018-06-14 |
Contravir Pharmaceuticals, Inc. |
Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
|
|
RU2757218C2
(ru)
|
2016-12-14 |
2021-10-12 |
Интервет Интернэшнл Б.В. |
Аминопиразолы в качестве селективных ингибиторов янус-киназы
|
|
SG11201908569QA
(en)
|
2017-03-21 |
2019-10-30 |
Arbutus Biopharma Corp |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
|
AU2018249822A1
(en)
|
2017-04-03 |
2019-10-31 |
Coherus Biosciences Inc. |
PPArgamma agonist for treatment of progressive supranuclear palsy
|
|
AR111464A1
(es)
|
2017-04-14 |
2019-07-17 |
Contravir Pharmaceuticals Inc |
Terapia combinada para el tratamiento de infecciones virales
|
|
DE202017002464U1
(de)
|
2017-05-09 |
2017-06-12 |
St. Lotus Biotech Corp. |
Pflanzliche Zusammensetzung zur Vorbeugung oder Linderung von ischämischem Schlaganfall
|
|
US11484543B2
(en)
|
2017-05-18 |
2022-11-01 |
The Rockefeller University |
Compositions and methods for diagnosing and treating diseases and disorders associated with mutant KCNJ5
|
|
EP4092013A1
(en)
|
2017-06-20 |
2022-11-23 |
Imbria Pharmaceuticals, Inc. |
Compositions and methods for increasing efficiency of cardiac metabolism
|
|
ES2926540T3
(es)
|
2017-08-08 |
2022-10-26 |
Chemocentryx Inc |
Inmunomoduladores macrocíclicos
|
|
BR112020003217A2
(pt)
|
2017-08-14 |
2020-10-06 |
Boehringer Ingelheim Animal Health USA Inc. |
compostos pesticidas e parasiticidas de pirazolisoxazolina
|
|
MA50665A
(fr)
|
2017-09-25 |
2020-08-05 |
Chemocentryx Inc |
Polythérapie utilisant un antagoniste du récepteur 2 de la chimiokine (ccr2) et un inhibiteur pd-1/pd-l1
|
|
EP3694504A4
(en)
|
2017-10-11 |
2021-07-14 |
ChemoCentryx, Inc. |
TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CRC2 ANTAGONISTS
|
|
EP3704122B1
(en)
|
2017-11-03 |
2021-09-01 |
Amgen Inc. |
Fused triazole agonists of the apj receptor
|
|
CN111818929A
(zh)
|
2017-11-27 |
2020-10-23 |
由卫生与公众服务部部长代表的***合众国 |
用于治疗和/或预防牙周疾病的化合物、组合物和方法
|
|
KR20200109316A
(ko)
|
2017-12-22 |
2020-09-22 |
케모센트릭스, 인크. |
C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물
|
|
WO2019141957A1
(en)
|
2018-01-19 |
2019-07-25 |
Cado Biotechnology Ivs |
N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof
|
|
WO2019157241A1
(en)
|
2018-02-08 |
2019-08-15 |
Boehringer Ingelheim Animal Health USA Inc. |
Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
|
|
CN112313221A
(zh)
|
2018-02-13 |
2021-02-02 |
比托邦制药有限公司 |
***素衍生物和缀合物以及其用途
|
|
EP3755311A4
(en)
|
2018-02-22 |
2021-11-10 |
ChemoCentryx, Inc. |
USEFUL INDANE-AMINES AS AN AGONISTS OF PD-L1
|
|
US10982210B2
(en)
|
2018-03-02 |
2021-04-20 |
Sixfold Bioscience Ltd. |
Compositions for delivery of cargo to cells
|
|
WO2019191032A1
(en)
|
2018-03-26 |
2019-10-03 |
Clear Creek Bio, Inc. |
Compositions and methods for inhibiting dihydroorotate dehydrogenase
|
|
WO2019190823A1
(en)
|
2018-03-28 |
2019-10-03 |
Vtv Therapeutics Llc |
Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
|
|
WO2019190822A1
(en)
|
2018-03-28 |
2019-10-03 |
Vtv Therapeutics Llc |
Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
|
|
US20190300526A1
(en)
|
2018-04-02 |
2019-10-03 |
Chemocentryx, Inc. |
PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
|
|
EP3552605A1
(en)
|
2018-04-11 |
2019-10-16 |
Univerzita Palackého V Olomouchi |
Mcoppb for use as medicament
|
|
WO2019213006A1
(en)
|
2018-05-01 |
2019-11-07 |
Amgen Inc. |
Substituted pyrimidinones as agonists of the apj receptor
|
|
WO2019231739A1
(en)
|
2018-05-29 |
2019-12-05 |
Cersci Therapeutics, Inc. |
Compounds for pain treatment, compositions comprising same, and methods of using same
|
|
WO2019236984A1
(en)
|
2018-06-08 |
2019-12-12 |
The Medical College Of Wisconsin, Inc. |
Methods of treating vascular leakage using cxcl12 peptides
|
|
IL279977B2
(en)
|
2018-07-09 |
2024-06-01 |
Boehringer Ingelheim Animal Health Usa Inc |
Heterocyclic anthelmintic compounds
|
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
CA3111275A1
(en)
|
2018-09-06 |
2020-03-12 |
Innopharmascreen Inc. |
Methods and compositions for treatment of asthma or parkinson's disease
|
|
WO2020076668A1
(en)
|
2018-10-10 |
2020-04-16 |
Vtv Therapeutics Llc |
Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
|
|
US20210353617A1
(en)
|
2018-10-17 |
2021-11-18 |
Imbria Pharmaceuticals, Inc. |
Methods of treating rheumatic diseases using trimetazidine-based compounds
|
|
US12030872B2
(en)
|
2018-10-31 |
2024-07-09 |
Merck Sharp & Dohme Llc |
N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
|
|
WO2020092845A1
(en)
|
2018-11-01 |
2020-05-07 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
|
WO2020112374A1
(en)
|
2018-11-20 |
2020-06-04 |
Boehringer Ingelheim Animal Health USA Inc. |
Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof
|
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
WO2020159565A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
|
WO2020159588A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
|
JP2022526901A
(ja)
|
2019-03-19 |
2022-05-27 |
ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド |
駆虫性アザベンゾチオフェンおよびアザベンゾフラン化合物
|
|
CA3139109A1
(en)
|
2019-05-09 |
2020-11-12 |
The Feinstein Institutes For Medical Research |
Hmgb1 antagonist
|
|
US20200377518A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
|
EP3980412A4
(en)
|
2019-06-06 |
2023-05-31 |
Merck Sharp & Dohme LLC |
INDAZOLE 5-, 6-DISUBSTITUTED, 1-PYRAZOLYL DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
|
|
BR112022000113A2
(pt)
|
2019-07-08 |
2022-03-15 |
Activesite Pharmaceuticals Inc |
Processos para preparação de inibidores de calicreí-na de plasma
|
|
JP2022539830A
(ja)
|
2019-07-10 |
2022-09-13 |
ケモセントリックス，インコーポレイティド |
Ｐｄ－ｌ１阻害剤としてのインダン
|
|
BR112022001418A2
(pt)
|
2019-08-08 |
2022-06-07 |
Rigel Pharmaceuticals Inc |
Compostos e método para tratar a síndrome de liberação de citocinas
|
|
JP2022544276A
(ja)
|
2019-08-14 |
2022-10-17 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
サイトカイン放出症候群をブロック又は改善する方法
|
|
US10792360B1
(en)
|
2019-11-21 |
2020-10-06 |
Chemocentryx, Inc. |
Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
|
|
WO2021123394A1
(en)
|
2019-12-20 |
2021-06-24 |
University Of Copenhagen |
G protein-coupled receptor modulators and a pharmaceutical composition
|
|
AU2021244255A1
(en)
|
2020-03-27 |
2022-09-29 |
Aclaris Therapeutics, Inc. |
Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds
|
|
TW202203916A
(zh)
|
2020-03-31 |
2022-02-01 |
美商卡默森屈有限公司 |
使用ｃｃｒ９抑制劑及抗ｉｌ—２３阻斷抗體治療發炎性腸道疾病的組成物及方法
|
|
CN116134144A
(zh)
|
2020-04-23 |
2023-05-16 |
Az治疗股份有限公司 |
细胞的hla-i类mhc消融
|
|
AU2021260118A1
(en)
|
2020-04-24 |
2022-11-17 |
Nuvamid Sa |
Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
|
|
EP3901160A1
(en)
|
2020-04-25 |
2021-10-27 |
Nuvamid SA |
Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
|
|
US11357865B2
(en)
|
2020-04-27 |
2022-06-14 |
Sixfold Bioscience Ltd. |
Compositions containing nucleic acid nanoparticles with modular functionality
|
|
EP4142704A1
(en)
|
2020-04-30 |
2023-03-08 |
Tobia, Annette M. |
Compositions and methods for treating cytokine storms
|
|
WO2021243275A2
(en)
|
2020-05-28 |
2021-12-02 |
Aztherapies, Inc. |
Car-treg-based therapies for treating neurgdegenerative diseases
|
|
EP4185589A1
(en)
|
2020-05-29 |
2023-05-31 |
Boehringer Ingelheim Animal Health USA Inc. |
Anthelmintic heterocyclic compounds
|
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
CA3188796A1
(en)
|
2020-07-07 |
2022-01-13 |
Atxa Therapeutics Limited |
Thromboxane receptor antagonist formulations
|
|
EP4182326A1
(en)
|
2020-07-17 |
2023-05-24 |
Université de Bretagne Occidentale |
New glycolipids and use thereof as sk3 ion channel modulators
|
|
WO2022029275A1
(en)
|
2020-08-06 |
2022-02-10 |
Nuvamid Sa |
Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19
|
|
WO2022029287A1
(en)
|
2020-08-07 |
2022-02-10 |
Nuvamid Sa |
Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity
|
|
JP2023538871A
(ja)
|
2020-08-12 |
2023-09-12 |
ティーエックスピー ファーマ エージー |
エキセンジン－４ペプチド類似体
|
|
KR20230090336A
(ko)
|
2020-10-13 |
2023-06-21 |
베타바이브 리미티드 |
당뇨병 및 관련된 대사성 질환을 치료하기 위한 방법 및 화합물
|
|
GB202017255D0
(en)
|
2020-10-30 |
2020-12-16 |
Queens Univ Of Belfast |
Immunomodulatory agent
|
|
GB202017251D0
(en)
|
2020-10-30 |
2020-12-16 |
Queens Univ Of Belfast |
Neurodegenerative treatment
|
|
US11331293B1
(en)
|
2020-11-17 |
2022-05-17 |
Neuroderm, Ltd. |
Method for treatment of Parkinson's disease
|
|
US11213502B1
(en)
|
2020-11-17 |
2022-01-04 |
Neuroderm, Ltd. |
Method for treatment of parkinson's disease
|
|
US11844754B2
(en)
|
2020-11-17 |
2023-12-19 |
Neuroderm, Ltd. |
Methods for treatment of Parkinson's disease
|
|
US11969422B2
(en)
|
2020-12-10 |
2024-04-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine
|
|
US11730733B2
(en)
|
2020-12-10 |
2023-08-22 |
Imbria Pharmaceuticals, Inc. |
Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
|
|
US11793807B2
(en)
|
2020-12-10 |
2023-10-24 |
Imbria Pharmaceuticals, Inc. |
Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
|
|
RS65326B1
(sr)
|
2020-12-18 |
2024-04-30 |
Nuvamid Sa |
Derivati nikotinamid mononukleotida u lečenju i prevenciji bolesti srpastih ćelija
|
|
US11717515B2
(en)
|
2020-12-22 |
2023-08-08 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
JP2024506041A
(ja)
|
2021-02-08 |
2024-02-08 |
ボシュ ヘルス アイルランド リミテッド |
潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド
|
|
WO2022184685A1
(en)
|
2021-03-01 |
2022-09-09 |
Nuvamid Sa |
Nicotinamide mononucleotide derivatives and use thereof for the treatment and/or prevention of long covid-19
|
|
EP4070799A1
(en)
|
2021-04-08 |
2022-10-12 |
Nuvamid SA |
Compositions for the improvement of sport performance
|
|
EP4079310A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
|
|
EP4079311A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
|
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|
|
WO2022254425A1
(en)
|
2021-05-31 |
2022-12-08 |
Cannabotech Ltd. |
Compositions comprising a cannabinoid and uses thereof
|
|
CA3222984A1
(en)
|
2021-06-17 |
2022-12-22 |
Laurent GARCON |
Nicotinamide mononucleotide derivatives and use thereof for the treatment of heart failure with preserved ejection fraction
|
|
WO2022263676A1
(en)
|
2021-06-18 |
2022-12-22 |
University Of Copenhagen |
Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
|
|
CA3227520A1
(en)
|
2021-08-02 |
2023-02-09 |
Laurent GARCON |
Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
|
|
EP4415744A1
(en)
|
2021-10-12 |
2024-08-21 |
Betavive Ltd. |
Peptides and fragments for treating diabetes and associated metabolic diseases
|
|
US20240116945A1
(en)
|
2022-09-02 |
2024-04-11 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
|
WO2024052895A1
(en)
|
2022-09-06 |
2024-03-14 |
Hadasit Medical Research Services And Development Ltd |
Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
|
|
US20240208987A1
(en)
|
2022-10-25 |
2024-06-27 |
Merck Sharp & Dohme Llc |
Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
|
|
US20240207425A1
(en)
|
2022-12-14 |
2024-06-27 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|
|
US20240270716A1
(en)
|
2023-01-20 |
2024-08-15 |
Epics Therapeutics |
Piperidine derivatives as mettl3 inhibitors
|